<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0509234132
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ORAMAX 150MG CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUCONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Oramax </strong>is one of a group of medicines called &ldquo;antifungals&rdquo;. The active substance is fluconazole.</p><p><strong>Oramax </strong>is used to treat infections caused by fungi and may also be used to stop you from getting a candidal infection. The most common cause of fungal infections is a yeast called <em>Candida</em>.&nbsp;</p><p><strong><u>Adults </u></strong></p><p><strong>You might be given this medicine by your doctor to treat the following types of fungal infections: </strong></p><p>-&nbsp; Cryptococcal meningitis - a fungal infection in the brain</p><p>-&nbsp; Coccidioidomycosis - a disease of the bronchopulmonary system</p><p>-&nbsp; Infections caused by Candida and found in the blood stream, body organs (e.g. heart, lungs) or urinary tract</p><p>-&nbsp; Mucosal thrush - infection affecting the lining of the mouth, throat and denture sore mouth</p><p>-&nbsp; Genital thrush - infection of the vagina or penis</p><p>-&nbsp; Skin infections - e.g. athlete&#39;s foot, ringworm, jock itch, nail infection</p><p><strong>You might also be given Oramax</strong> <strong>to: </strong></p><p>-&nbsp; stop cryptococcal meningitis from coming back</p><p>-&nbsp; stop mucosal thrush from coming back</p><p>-&nbsp; reduce recurrence of vaginal thrush</p><p>-&nbsp; stop you from getting an infection caused by Candida (if your immune system is weak and not working properly)</p><p><strong><u>Children and adolescents (0 to 17 years old)</u></strong></p><p><strong>You might be given this medicine by your doctor to treat the following types of fungal infections: </strong></p><p>-&nbsp; Mucosal thrush - infection affecting the lining of the mouth, throat</p><p>-&nbsp; Infections caused by Candida and found in the blood stream, body organs (e.g. heart, lungs) or urinary tract</p><p>-&nbsp; Cryptococcal meningitis - a fungal infection in the brain</p><p><strong>You might also be given Oramax</strong> <strong>to: </strong></p><p>-&nbsp; stop you from getting an infection caused by Candida (if your immune system is weak and not working properly).</p><p>-&nbsp; stop cryptococcal meningitis from coming back</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Oramax:</strong></p><p>&bull;&nbsp; if you are allergic to fluconazole, to other medicines you have taken to treat fungal infections or to any of the other ingredients of this medicine (listed in section 6). The symptoms may include itching, reddening of the skin or difficulty in breathing</p><p>&bull;&nbsp; if you are taking astemizole, terfenadine (antihistamine medicines for allergies)</p><p>&bull;&nbsp; if you are taking cisapride (used for stomach upsets)</p><p>&bull;&nbsp; if you are taking pimozide (used for treating mental illness)</p><p>&bull;&nbsp; if you are taking quinidine (used for treating heart arrhythmia)</p><p>&bull;&nbsp; if you are taking erythromycin (an antibiotic for treating infections)</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking <strong>Oramax</strong></p><p>&bull;&nbsp; if you have liver or kidney problems</p><p>&bull;&nbsp; if you suffer from heart disease, including heart rhythm problems</p><p>&bull;&nbsp; if you have abnormal levels of potassium, calcium or magnesium in your blood</p><p>&bull;&nbsp; if you develop severe skin reactions (itching, reddening of the skin or difficulty in breathing)</p><p>&bull;&nbsp; if you develop signs of &lsquo;adrenal insufficiency&rsquo; where the adrenal glands do not produce adequate amounts of certain steroid hormones such as cortisol (chronic, or long lasting fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain)</p><p>&bull;&nbsp; if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking fluconazole</p><p>Serious skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with fluconazole treatment. Stop taking <strong>Oramax </strong>and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.</p><p>Talk to your doctor or pharmacist if the fungal infection does not improve, as alternative antifungal therapy may be needed.</p><p><strong>Other medicines and Oramax </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor <strong>immediately </strong>if you are taking astemizole, terfenadine (an antihistamine for treating allergies) or cisapride (used for stomach upsets) or pimozide (used for treating mental illness) or quinidine (used for treating heart arrhythmia) or erythromycin (an antibiotic for treating infections) as these should not be taken with <strong>Oramax</strong> (see section: &ldquo;Do not take <strong>Oramax</strong> if you&rdquo;).</p><p>There are some medicines that may interact with <strong>Oramax</strong>. Make sure your doctor knows if you are taking any of the following medicines as a dose adjustment or monitoring may be required to check that the medicines are still having the desired effect:</p><p>&bull;&nbsp; rifampicin or rifabutin (antibiotics for infections)</p><p>&bull;&nbsp; alfentanil, fentanyl (used as anaesthetic)</p><p>&bull;&nbsp; amitriptyline, nortriptyline (used as anti-depressant)</p><p>&bull;&nbsp; amphotericin B, voriconazole (anti-fungal)</p><p>&bull;&nbsp; medicines that thin the blood to prevent blood clots (warfarin or similar medicines)</p><p>&bull;&nbsp; benzodiazepines (midazolam, triazolam or similar medicines) used to help you sleep or for anxiety</p><p>&bull;&nbsp; carbamazepine, phenytoin (used for treating fits)</p><p>&bull;&nbsp; nifedipine, isradipine, amlodipine, verapamil, felodipine and losartan (for hypertension - high blood pressure)</p><p>&bull;&nbsp; olaparib (used for treating ovarian cancer)</p><p>&bull;&nbsp; ciclosporin, everolimus, sirolimus or tacrolimus (to prevent transplant rejection)</p><p>&bull;&nbsp; cyclophosphamide, vinca alkaloids (vincristine, vinblastine or similar medicines) used for treating cancer</p><p>&bull;&nbsp; halofantrine (used for treating malaria)</p><p>&bull;&nbsp; statins (atorvastatin, simvastatin and fluvastatin or similar medicines) used for reducing high cholesterol levels</p><p>&bull;&nbsp; methadone (used for pain)</p><p>&bull;&nbsp; celecoxib, flurbiprofen, naproxen, ibuprofen, lornoxicam, meloxicam, diclofenac (Non-Steroidal Anti-Inflammatory Drugs (NSAID))</p><p>&bull;&nbsp; oral contraceptives</p><p>&bull;&nbsp; prednisone (steroid)</p><p>&bull;&nbsp; zidovudine, also known as AZT; saquinavir (used in HIV-infected patients)</p><p>&bull;&nbsp; medicines for diabetes such as chlorpropamide, glibenclamide, glipizide or tolbutamide</p><p>&bull;&nbsp; theophylline (used to control asthma)</p><p>&bull;&nbsp; tofacitinib (used for treating rheumatoid arthritis)</p><p>&bull;&nbsp; tolvaptan used to treat hyponatremia (low levels of sodium in your blood) or to slow kidney function decline</p><p>&bull;&nbsp; vitamin A (nutritional supplement)</p><p>&bull;&nbsp; ivacaftor (used for treating cystic fibrosis)</p><p>&bull;&nbsp; amiodarone (alone or combined with other drugs used for treating uneven heartbeats &lsquo;arrhythmias&rsquo;)</p><p>&bull;&nbsp; hydrochlorothiazide (a diuretic)</p><p>&bull;&nbsp; ibrutinib (used for treating blood cancer)</p><p>&bull;&nbsp; lurasidone (used to treat schizophrenia)</p><p><strong>Oramax with food and drink </strong></p><p>You can take your medicine with or without a meal.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>You should not take <strong>Oramax</strong> if you are pregnant, think you may be pregnant, are trying to become pregnant, unless your doctor has told you so.&nbsp; If you become pregnant while taking this medicine or within 1 week of the most recent dose, contact your doctor.</p><p>Fluconazole taken during the first trimester of pregnancy may increase the risk of miscarriage. Fluconazole taken at low doses during the first trimester may slightly increase the risk of a baby being born with birth defects affecting the bones and/or muscles.</p><p>You can continue breast-feeding after taking a single dose of 150 mg <strong>Oramax</strong>.</p><p>You should not breast-feed if you are taking a repeated dose of <strong>Oramax</strong>.</p><p><strong>Driving and using machines </strong></p><p>When driving vehicles or using machines, it should be taken into account that occasionally dizziness or fits may occur.</p><p><strong>Oramax contains lactose </strong></p><p>This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, please contact your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take your medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Swallow the capsule whole with a glass of water. It is best to take your capsules at the same time each day.</p><p>The recommended doses of this medicine for different infections are below:</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Adults</strong></p><p><strong><u>&nbsp;</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Condition</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>To treat cryptococcal meningitis</p></td><td style="vertical-align:top"><p>400 mg on the first day then 200 mg to 400 mg once daily for 6 to 8 weeks or longer if needed. Sometimes doses are increased up to 800 mg</p></td></tr><tr><td style="vertical-align:top"><p>To stop cryptococcal meningitis from coming back</p></td><td style="vertical-align:top"><p>200 mg once daily until you are told to stop</p></td></tr><tr><td style="vertical-align:top"><p>To treat coccidioidomycosis</p></td><td style="vertical-align:top"><p>200 mg to 400 mg once daily from 11 months for up to 24 months or longer if needed. Sometimes doses are increased up to 800 mg</p></td></tr><tr><td style="vertical-align:top"><p>To treat internal fungal infections caused by Candida</p></td><td style="vertical-align:top"><p>800 mg on the first day then 400 mg once daily until you are told to stop</p></td></tr><tr><td style="vertical-align:top"><p>To treat mucosal infections affecting the lining of mouth, throat and denture sore mouth</p></td><td style="vertical-align:top"><p>200 mg to 400 mg on the first day then 100 mg to 200 mg until you are told to stop</p></td></tr><tr><td style="vertical-align:top"><p>To treat mucosal thrush &ndash; dose depends on where the infection is located</p></td><td style="vertical-align:top"><p>50 mg to 400 mg once daily for 7 to 30 days until you are told to stop</p></td></tr><tr><td style="vertical-align:top"><p>To stop mucosal infections affecting the lining of mouth, throat from coming back</p></td><td style="vertical-align:top"><p>100 mg to 200 mg once daily, or 200 mg 3 times a week, while you are at risk of getting an infection</p></td></tr><tr><td style="vertical-align:top"><p>To treat genital thrush</p></td><td style="vertical-align:top"><p>150 mg as a single dose</p></td></tr><tr><td style="vertical-align:top"><p>To reduce recurrence of vaginal thrush</p></td><td style="vertical-align:top"><p>150 mg every third day for a total of 3 doses (day 1, 4 and 7) and then once a week for 6 months while you are at risk of getting an infection</p></td></tr><tr><td style="vertical-align:top"><p>To treat fungal skin and nail infections</p></td><td style="vertical-align:top"><p>Depending on the site of the infection 50 mg once daily, 150 mg once weekly, 300 to 400 mg once weekly for 1 to 4 weeks (Athlete&rsquo;s foot may be up to 6 weeks, for nail infection treatment until infected nail is replaced)</p></td></tr><tr><td style="vertical-align:top"><p>To stop you from getting an infection caused by Candida (if your immune system is weak and not working properly)</p></td><td style="vertical-align:top"><p>200 mg to 400 mg once daily while you are at risk of getting an infection</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Adolescents from 12 to 17 years old</strong></p><p>Follow the dose prescribed by your doctor (either adults or children posology).</p><p><strong>Children to 11 years old</strong></p><p>The maximum dose for children is 400 mg daily.</p><p>The dose will be based on the child&rsquo;s weight in kilograms.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Condition</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mucosal thrush and throat infections caused by <em>Candida </em>&ndash; dose and duration depends on the severity of the infection and on where the infection is located</p></td><td style="vertical-align:top"><p>3 mg per kg of body weight once daily (6 mg per kg of body weight might be given on the first day)</p></td></tr><tr><td style="vertical-align:top"><p>Cryptococcal meningitis or internal fungal infections caused by <em>Candida</em></p></td><td style="vertical-align:top"><p>6 mg to 12 mg per kg of body weight once daily</p></td></tr><tr><td style="vertical-align:top"><p>To stop cryptococcal meningitis from coming back</p></td><td style="vertical-align:top"><p>6 mg per kg of body weight once daily</p></td></tr><tr><td style="vertical-align:top"><p>To stop children from getting an infection caused by <em>Candida </em>(if their immune system is not working properly)</p></td><td style="vertical-align:top"><p>3 mg to 12 mg per kg of body weight once daily</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Use in children 0 to 4 weeks of age</strong></p><p>-&nbsp; <u>Use in children of 3 to 4 weeks of age:</u></p><p>The same dose as above but given once every 2 days. The maximum dose is 12 mg per kg of body weight every 48 hours.</p><p>-&nbsp; <u>Use in children less than 2 weeks old:</u></p><p>The same dose as above but given once every 3 days. The maximum dose is 12 mg per kg of body weight every 72 hours.</p><p><strong>Elderly</strong></p><p>The usual adult dose should be given unless you have kidney problems.</p><p><strong>Patients with kidney problems</strong></p><p>Your doctor may change your dose, depending on your kidney function.</p><p><strong>If you take more Oramax</strong> <strong>than you should </strong></p><p>Taking too many capsules at once may make you unwell. Contact your doctor or your nearest hospital casualty department at once. The symptoms of a possible overdose may include hearing, seeing, feeling and thinking things that are not real (hallucination and paranoid behaviour). Symptomatic treatment (with supportive measures and gastric lavage if necessary) may be adequate.</p><p><strong>If you forget to take Oramax</strong></p><p>Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, do not take the dose that you missed.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. &nbsp;</p><p>Stop taking <strong>Oramax</strong> and seek medical attention <strong>immediately</strong> if you notice any of the following symptoms:</p><p>&bull;&nbsp; widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome)</p><p>A few people develop <strong>allergic reactions </strong>although serious allergic reactions are rare<strong>. </strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. If you get any of the following symptoms, <strong>tell your doctor immediately. </strong></p><p>&bull;&nbsp; sudden wheezing, difficulty in breathing or tightness in the chest</p><p>&bull;&nbsp; swelling of eyelids, face or lips</p><p>&bull;&nbsp; itching all over the body, reddening of the skin or itchy red spots</p><p>&bull;&nbsp; skin rash</p><p>&bull;&nbsp; severe skin reactions such as a rash that causes blistering (this can affect the mouth and tongue).</p><p><strong>Oramax</strong> may affect your liver. The signs of liver problems include:</p><p>&bull;&nbsp; tiredness</p><p>&bull;&nbsp; loss of appetite</p><p>&bull;&nbsp; vomiting</p><p>&bull;&nbsp; yellowing of your skin or the whites of your eyes (jaundice)</p><p>If any of these happen, stop taking <strong>Oramax</strong> and <strong>tell your doctor immediately. </strong></p><p><strong>Other side effects: </strong></p><p>Additionally, if any of the following side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p><strong>Common side effects (may affect up to 1 in 10 people) are: </strong></p><p>&bull;&nbsp; headache</p><p>&bull;&nbsp; stomach discomfort, diarrhoea, feeling sick, vomiting</p><p>&bull;&nbsp; increases in blood tests of liver function</p><p>&bull;&nbsp; rash</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) are: </strong></p><p>&bull;&nbsp; reduction in red blood cells which can make skin pale and cause weakness or breathlessness</p><p>&bull;&nbsp; decreased appetite</p><p>&bull;&nbsp; inability to sleep, feeling drowsy</p><p>&bull;&nbsp; fit, dizziness, sensation of spinning, tingling, pricking or numbness, changes in sense of&nbsp; taste</p><p>&bull;&nbsp; constipation, difficult digestion, wind, dry mouth</p><p>&bull;&nbsp; muscle pain</p><p>&bull;&nbsp; liver damage and yellowing of the skin and eyes (jaundice)</p><p>&bull;&nbsp; wheals, blistering (hives), itching, increased sweating</p><p>&bull;&nbsp; tiredness, general feeling of being unwell, fever</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people) are: </strong></p><p>&bull;&nbsp; lower than normal white blood cells that help defend against infections and blood cells that help to stop bleeding</p><p>&bull;&nbsp; red or purple discoloration of the skin which may be caused by low platelet count, other blood cell changes</p><p>&bull;&nbsp; blood chemistry changes (high blood levels of cholesterol, fats)</p><p>&bull;&nbsp; low blood potassium</p><p>&bull;&nbsp; shaking</p><p>&bull;&nbsp; abnormal electrocardiogram (ECG), change in heart rate or rhythm</p><p>&bull;&nbsp; liver failure</p><p>&bull;&nbsp; allergic reactions (sometimes severe), including widespread blistering rash and skin peeling, severe skin reactions, swelling of the lips or face</p><p>&bull;&nbsp; hair loss</p><p><strong>Frequency not known, but may occur (cannot be estimated from the available data): </strong></p><p>&bull;&nbsp; hypersensitivity reaction with skin rash, fever, swollen glands, increase in a type of white blood cell (eosinophilia) and inflammation of internal organs (liver, lungs, heart, kidneys and large intestine) (Drug Reaction or rash with Eosinophilia and Systemic Symptoms (DRESS))</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of side effects </u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p>&sect; <strong>Saudi</strong><strong> Arabia:</strong></p><p><strong>&nbsp; &nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p>-&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp; Website:<strong> </strong>https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other</strong><strong> </strong><strong>GCC States:</strong></p><p>-&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp; Do not take <strong>Oramax </strong>after the expiry date which is stated on the carton and on the blister.</p><p>-&nbsp; Store below 30&deg;C.</p><p>-&nbsp; Do not take<strong> Oramax </strong>if you notice any visible sign of deterioration.</p><p>-&nbsp; Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is fluconazole. Each capsule contains 150mg of fluconazole</p><p>The other ingredients: Lactose monohydrate, maize starch, sodium lauryl sulphate, colloidal silicone dioxide, magnesium stearate and hard gelatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oramax capsule is available in pack of 1 capsule
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/08/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>أوراماكس </strong>ينتمي إلى مجموعة من الأدوية التي تعرف باسم &quot;مضادات الفطريات&quot;. فلوكونازول<strong> </strong>المادة الفعالة في هذا الدواء.</p><p dir="RTL">يستخدم <strong>أوراماكس </strong>لعلاج العدوى الناجمة عن الفطريات وكما قد يستخدم للحد من الإصابة بداء المبيضات. الخميرة التي تعرف باسم الكانديدا تعد السبب الأكثر شيوعاً لحدوث العدوى الفطرية.</p><p dir="RTL"><strong><u>البالغون:</u></strong></p><p dir="RTL"><strong>قد يتم إعطائك هذا الدواء من قبل طبيبك المعالج لعلاج حالات العدوى الفطرية التالية:</strong></p><p dir="RTL">-&nbsp; التهاب السحايا الناجم عن فطريات المستخفيات&nbsp; &ndash; العدوى الفطرية التي تصيب الدماغ</p><p dir="RTL">-&nbsp; الحمى الناجمة عن الفطار الكرواني&ndash; حالة مرضية التي تصيب الجهاز القصبي الرئوي</p><p dir="RTL">-&nbsp; العدوى الناجمة عن الكانديدا والتي تتواجد في مجرى الدم، أعضاء الجسم (على سبيل المثال القلب، الرئتين) أو المسالك البولية</p><p dir="RTL">-&nbsp; داء القلاع المخاطي - العدوى التي تُصيب بطانة الفم والحلق وتسبب التهاب الفم تحت تركيبات الأسنان الصناعية</p><p dir="RTL">-&nbsp; داء القلاع التناسلي - العدوى التي تصيب المهبل أو القضيب.</p><p dir="RTL">-&nbsp; عدوى الجلد - على سبيل المثال القدم الرياضي، القوباء الحلقية، حكة جوك وعدوى الأظافر.</p><p dir="RTL"><strong>كما قد يتم إعطائك أوراماكس في الحالات التالية:</strong></p><p dir="RTL">-&nbsp; للحد من معاودة حدوث التهاب السحايا الناجم عن فطريات المستخفيات&nbsp;</p><p dir="RTL">-&nbsp; للحد من معاودة حدوث داء القلاع المخاطي</p><p dir="RTL">-&nbsp; لتقليل معدل حدوث داء القلاع المهبلي</p><p dir="RTL">-&nbsp; للحد من حدوث العدوى الناجمة عن الكانديدا (في حال كان الجهاز المناعي ضعيف ولا يعمل بصورة كافية)</p><p dir="RTL"><strong><u>الأطفال والمراهقون (بعمر يتراوح منذ الولادة إلى عمر 17 سنة)</u></strong></p><p dir="RTL"><strong>قد يصف الطبيب المعالج هذا الدواء لعلاج حالات العدوى الفطرية التالية:</strong></p><p dir="RTL">-&nbsp; داء القلاع المخاطي - العدوى التي تُصيب بطانة الفم والحلق</p><p dir="RTL">-&nbsp; العدوى الناجمة عن الكانديدا والتي تتواجد في مجرى&nbsp; الدم، أعضاء الجسم (على سبيل المثال القلب، الرئتين) أو المسالك البولية</p><p dir="RTL">-&nbsp; التهاب السحايا الناجم عن فطريات المستخفيات&nbsp; &ndash; العدوى الفطرية التي تصيب الدماغ</p><p dir="RTL"><strong>كما قد يتم استخدام أوراماكس في الحالات التالية:</strong></p><p dir="RTL">-&nbsp; للحد من حدوث العدوى الناجمة عن الكانديدا (في حال كان الجهاز المناعي ضعيف ولا يعمل بصورة كافية)</p><p dir="RTL">-&nbsp; للحد من معاودة حدوث التهاب السحايا الناجم عن فطريات المستخفيات&nbsp; &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عليك عدم تناول أوراماكس في الحالات التالية</strong></p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من الحساسية تجاه فلوكونازول، أو الأدوية الأخرى التي قد تتناولها لمعالجة العدوى الفطرية أو أياً من المكونات الأخرى (انظر البند رقم 6)، قد تتضمن الأعراض على الحكة، احمرار الجلد أو صعوبة التنفس.</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول أستيميزول، تيرفينادين (الأدوية المضادة للهيستامين لعلاج حالات الحساسية)</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول سيسابريد (يستخدم لعلاج&nbsp; اضطرابات المعدة)</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول بيموزيد (يستخدم لعلاج الأمراض النفسية)</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول كينيدين (يستخدم لعلاج عدم انتظام ضربات القلب)</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول إريثروميسين (مضاد حيوي لعلاج حالات العدوى)</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل تناول <strong>أوراماكس</strong>:</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من اضطرابات في الكبد أو الكلى</p><p dir="RTL">&bull; إذا كنت تعاني من أمراض القلب بما في ذلك مشاكل في ضربات القلب</p><p dir="RTL">&bull; إذا كنت تعاني من مستويات غير طبيعية من البوتاسيوم، الكالسيوم أو المغنيسيوم في الدم</p><p dir="RTL">&bull; إذا كنت تعاني من ردود فعل جلدية حادة (حكة، احمرار الجلد أو صعوبة في التنفس)</p><p dir="RTL">&bull; إذا كنت تعاني من علامات تدل على &quot;قصور الغدة الكظرية&quot; حيث لا تنتج الغدد الكظرية كميات كافية من بعض هرمونات الستيرويد مثل الكورتيزول (شعور دائم بالتعب يدوم لفترات طويلة، ضعف العضلات، فقدان الشهية، فقدان الوزن، وألم في البطن)</p><p dir="RTL">&bull; إذا عانيت مسبقاً من طفح جلدي شديد، تقشر الجلد، بثور و/أو تقرحات فموية بعد تناول فلوكونازول<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL">سجل حدوث تفاعلات جلدية خطيرة بما في ذلك التفاعلات الدوائية مع فرط الحمضات والأعراض الجهازية (متلازمة دريس) المرتبط مع تلقي العلاج باستخدام فلوكونازول. يرجى منك التوقف عن تناول <strong>أوراماكس</strong> وطلب العناية الطبية على الفور، إذا لاحظت أيًا من الأعراض المرتبطة بالتفاعلات الجلدية الخطيرة المذكورة في البند رقم 4.</p><p dir="RTL">يرجى منك التحدث إلى طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا لم تتحسن حالة العدوى الفطرية، فقد تكون بحاجة إلى تلقي العلاج البديل لمضاد الفطريات.</p><p dir="RTL"><strong>تناول الأدوية الأخرى و أوراماكس</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه في حال كنت تتناول، تناولت أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">يجب عليك إخبار طبيبك المعالج <strong>على الفور</strong> إذا كنت تتناول أستيميزول، تيرفينادين (مضادات للهيستامين تستخدم لعلاج حالات الحساسية) أو سيسابريد (تستخدم لعلاج اضطرابات المعدة) أو بيموزيد (يستخدم لعلاج الأمراض النفسية) أو كينيدين (يستخدم لعلاج عدم انتظام ضربات القلب) أو الإريثروميسين (مضاد حيوي يستخدم لعلاج حالات العدوى) حيث أنه يجب عدم تناول <strong>أوراماكس</strong> مع هذه الأدوية ( انظر بند &quot; يجب عليك عدم تناول <strong>أوراماكس</strong> في الحالات التالية&quot;).</p><p dir="RTL">قد تتداخل بعض الأدوية مع <strong>أوراماكس</strong>. احرص على إخبار طبيبك المعالج إذا كنت تتناول أياً من الأدوية التالية، قد يكون هناك حاجة إلى تعديل مقدار الجرعة أو مراقبتها، لمعرفة ما إذا كانت هذه الأدوية لا تزال تعمل بالتأثير المطلوب:</p><p dir="RTL">&bull; ريفامبيسين أو ريفابيوتين (مضادات حيوية لعلاج حالات العدوى)</p><p dir="RTL">&bull; ألفينتانيل، فنتانيل (تستخدم للتخدير)</p><p dir="RTL">&bull; أميتريبتيلين ونورتريبتيلين (تستخدم&nbsp; كأدوية مضادة للاكتئاب)</p><p dir="RTL">&bull; أمفوتريسين &nbsp;بي، فوريكونازول (تستخدم&nbsp; كأدوية مضادة للفطريات)</p><p dir="RTL">&bull; الأدوية التي تعمل على تمييع الدم لمنع تجلط الدم (الوارفارين أو الأدوية المشابهة)</p><p dir="RTL">&bull; الأدوية من مجموعة البنزوديازيبين (ميدازولام، تريازولام أو الأدوية المشابهة) تستخدم لمساعدتك على النوم أو لعلاج حالات القلق</p><p dir="RTL">&bull; كاربامازيبين، الفينيتوين (التي تستخدم لعلاج النوبات التشنجية)</p><p dir="RTL">&bull; نيفيديبين، إسراديبين، أملوديبين، فيراباميل، فيلوديبين ولوسارتان (لارتفاع ضغط الدم)</p><p dir="RTL">&bull; أولاباريب (يستخدم لعلاج سرطان المبيض)</p><p dir="RTL">&bull; سيكلوسبورين، إيفيروليماس، سيروليماس أو تاكروليماس (لمنع رفض الجسم للأعضاء المزروعة)</p><p dir="RTL">&bull; سيكلوفوسفاميد، قلويدات الفينكا (الفينكريستين، فينبلاستين أو الأدوية المشابهة) أدوية تستخدم لعلاج السرطان</p><p dir="RTL">&bull; هالوفانترين (دواء يستخدم لعلاج الملاريا)</p><p dir="RTL">&bull; الأدوية من مجموعة الستاتين (أتورفاستاتين، سيمفاستاتين وفلوفاستاتين أو الأدوية المشابهة) أدوية تستخدم للحد من ارتفاع مستويات الكوليسترول</p><p dir="RTL">&bull; ميثادون (دواء يستخدم لعلاج الآلام)</p><p dir="RTL">&bull; سيليكوكسيب، فلوربيبروفين، نابروكسين، آيبوبروفين، لورنوكسيكام، ميلوكسيكام، ديكلوفيناك (الأدوية غير الستيرويدية المضادة للالتهابات)</p><p dir="RTL">&bull; حبوب منع الحمل الفموية</p><p dir="RTL">&bull; بريدنيزون (الستيرويد)</p><p dir="RTL">&bull; زيدوفودين، المعروف أيضاً باسم AZT، أو ساكوينافير (أدوية تستخدم للمرضى المصابين بفيروس نقص المناعة البشرية المكتسبة)</p><p dir="RTL">&bull; كلوربروباميد، غليبينكلاميد، غليبيزيد أو تولبوتاميد والتي تستخدم للسيطرة على مرض السكري</p><p dir="RTL">&bull; الثيوفيلين (يستخدم للسيطرة على نوبات الربو)</p><p dir="RTL">&bull; توفاسيتينيب (يستخدم لعلاج التهاب المفاصل الروماتويدي)</p><p dir="RTL">&bull; تولفابتان، يستخدم لعلاج نقص صوديوم الدم (انخفاض مستويات الصوديوم في الدم) أو للحد من تدهور وظائف الكلى</p><p dir="RTL">&bull; فيتامين (أ) (أحد المكملات الغذائية)</p><p dir="RTL">&bull; إيفاكفتور (دواء يستخدم لعلاج التليف الكيسي)</p><p dir="RTL">&bull; أميودارون (سواءً كان بمفرده أو بالتزامن مع أدوية أخرى تستخدم لعلاج عدم انتظام ضربات القلب&quot; دقات القلب غير المنتظمة&quot;)</p><p dir="RTL">&bull; هيدروكلوروثيازيد (دواء مدر للبول)</p><p dir="RTL">&bull; إيبروتينيب (يستخدم لعلاج سرطان الدم).</p><p dir="RTL">&bull; لوراسيدون (لعلاج داء الفصام).</p><p dir="RTL"><strong>تناول أوراماكس مع الطعام والشراب</strong></p><p dir="RTL">بإمكانك تناول الكبسولة مع أو بدون تناول وجبة الطعام.</p><p dir="RTL"><strong>الحمل، الرضاعة الطبيعية أو الخصوبة</strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه للحصول على المشورة الطبية قبل تناول هذا الدواء، في حال كنت حاملاً، تعتقدين بأنك حاملاً، تخططين كي تصبحي حاملاً أو ترضعي طفلك رضاعة طبيعية.</p><p dir="RTL">يجب عليك عدم تناول <strong>أوراماكس </strong>إذا كنت حاملاً، تعتقدين أنك حاملاً، تخططين كي تصبحي حاملاً ما لم يخبرك طبيبك بذلك. يرجى منك الاتصال في طبيبك المعالج، في حال كنت قد أصبحت حاملاً أثناء تناول هذا الدواء أو في غضون أسبوع واحد من تناول آخر جرعة من <strong>أوراماكس</strong>.</p><p dir="RTL">يجب عليك عدم تناول<strong> </strong>فلوكونازول<strong> </strong>أثناء الأشهر الثلاثة الأولى من الحمل، حيث أنه قد يؤدي إلى زيادة خطر حدوث الإجهاض. قد يؤدي تناول الفلوكونازول بجرعات منخفضة خلال الأشهر الثلاثة الأولى من الحمل إلى زيادة طفيفة في خطر ولادة طفل مصاب بعيوب خلقية التي تؤثر على العظام و/أو العضلات.</p><p dir="RTL">يمكنك مواصلة الرضاعة الطبيعية بعد تناول جرعة واحدة من <strong>أوراماكس</strong> 150<strong> </strong>ملغم.</p><p dir="RTL">يرجى منك عدم إرضاع طفلك رضاعة طبيعية في حال كنت تكررين تناول جرعات من <strong>أوراماكس</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب <strong>أوراماكس </strong>دوخة أو اختلاجات. يرجى منك عدم القيادة أو استخدام الآلات في حال حدوث ذلك لك.</p><p dir="RTL"><strong>يحتوي أوراماكس على اللاكتوز</strong></p><p dir="RTL">يحتوي هذا الدواء على اللاكتوز. يرجى منك استشارة طبيبك المعالج قبل تناول هذا الدواء،<strong> </strong>إذا كان قد أخبرك مسبقاً بأنك تعاني من مشكلة تتمثل في عدم القدرة على تحمل بعض أنواع السكر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عليك عدم تناول أوراماكس في الحالات التالية</strong></p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من الحساسية تجاه فلوكونازول، أو الأدوية الأخرى التي قد تتناولها لمعالجة العدوى الفطرية أو أياً من المكونات الأخرى (انظر البند رقم 6)، قد تتضمن الأعراض على الحكة، احمرار الجلد أو صعوبة التنفس.</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول أستيميزول، تيرفينادين (الأدوية المضادة للهيستامين لعلاج حالات الحساسية)</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول سيسابريد (يستخدم لعلاج&nbsp; اضطرابات المعدة)</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول بيموزيد (يستخدم لعلاج الأمراض النفسية)</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول كينيدين (يستخدم لعلاج عدم انتظام ضربات القلب)</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول إريثروميسين (مضاد حيوي لعلاج حالات العدوى)</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل تناول <strong>أوراماكس</strong>:</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من اضطرابات في الكبد أو الكلى</p><p dir="RTL">&bull; إذا كنت تعاني من أمراض القلب بما في ذلك مشاكل في ضربات القلب</p><p dir="RTL">&bull; إذا كنت تعاني من مستويات غير طبيعية من البوتاسيوم، الكالسيوم أو المغنيسيوم في الدم</p><p dir="RTL">&bull; إذا كنت تعاني من ردود فعل جلدية حادة (حكة، احمرار الجلد أو صعوبة في التنفس)</p><p dir="RTL">&bull; إذا كنت تعاني من علامات تدل على &quot;قصور الغدة الكظرية&quot; حيث لا تنتج الغدد الكظرية كميات كافية من بعض هرمونات الستيرويد مثل الكورتيزول (شعور دائم بالتعب يدوم لفترات طويلة، ضعف العضلات، فقدان الشهية، فقدان الوزن، وألم في البطن)</p><p dir="RTL">&bull; إذا عانيت مسبقاً من طفح جلدي شديد، تقشر الجلد، بثور و/أو تقرحات فموية بعد تناول فلوكونازول<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL">سجل حدوث تفاعلات جلدية خطيرة بما في ذلك التفاعلات الدوائية مع فرط الحمضات والأعراض الجهازية (متلازمة دريس) المرتبط مع تلقي العلاج باستخدام فلوكونازول. يرجى منك التوقف عن تناول <strong>أوراماكس</strong> وطلب العناية الطبية على الفور، إذا لاحظت أيًا من الأعراض المرتبطة بالتفاعلات الجلدية الخطيرة المذكورة في البند رقم 4.</p><p dir="RTL">يرجى منك التحدث إلى طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا لم تتحسن حالة العدوى الفطرية، فقد تكون بحاجة إلى تلقي العلاج البديل لمضاد الفطريات.</p><p dir="RTL"><strong>تناول الأدوية الأخرى و أوراماكس</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه في حال كنت تتناول، تناولت أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">يجب عليك إخبار طبيبك المعالج <strong>على الفور</strong> إذا كنت تتناول أستيميزول، تيرفينادين (مضادات للهيستامين تستخدم لعلاج حالات الحساسية) أو سيسابريد (تستخدم لعلاج اضطرابات المعدة) أو بيموزيد (يستخدم لعلاج الأمراض النفسية) أو كينيدين (يستخدم لعلاج عدم انتظام ضربات القلب) أو الإريثروميسين (مضاد حيوي يستخدم لعلاج حالات العدوى) حيث أنه يجب عدم تناول <strong>أوراماكس</strong> مع هذه الأدوية ( انظر بند &quot; يجب عليك عدم تناول <strong>أوراماكس</strong> في الحالات التالية&quot;).</p><p dir="RTL">قد تتداخل بعض الأدوية مع <strong>أوراماكس</strong>. احرص على إخبار طبيبك المعالج إذا كنت تتناول أياً من الأدوية التالية، قد يكون هناك حاجة إلى تعديل مقدار الجرعة أو مراقبتها، لمعرفة ما إذا كانت هذه الأدوية لا تزال تعمل بالتأثير المطلوب:</p><p dir="RTL">&bull; ريفامبيسين أو ريفابيوتين (مضادات حيوية لعلاج حالات العدوى)</p><p dir="RTL">&bull; ألفينتانيل، فنتانيل (تستخدم للتخدير)</p><p dir="RTL">&bull; أميتريبتيلين ونورتريبتيلين (تستخدم&nbsp; كأدوية مضادة للاكتئاب)</p><p dir="RTL">&bull; أمفوتريسين &nbsp;بي، فوريكونازول (تستخدم&nbsp; كأدوية مضادة للفطريات)</p><p dir="RTL">&bull; الأدوية التي تعمل على تمييع الدم لمنع تجلط الدم (الوارفارين أو الأدوية المشابهة)</p><p dir="RTL">&bull; الأدوية من مجموعة البنزوديازيبين (ميدازولام، تريازولام أو الأدوية المشابهة) تستخدم لمساعدتك على النوم أو لعلاج حالات القلق</p><p dir="RTL">&bull; كاربامازيبين، الفينيتوين (التي تستخدم لعلاج النوبات التشنجية)</p><p dir="RTL">&bull; نيفيديبين، إسراديبين، أملوديبين، فيراباميل، فيلوديبين ولوسارتان (لارتفاع ضغط الدم)</p><p dir="RTL">&bull; أولاباريب (يستخدم لعلاج سرطان المبيض)</p><p dir="RTL">&bull; سيكلوسبورين، إيفيروليماس، سيروليماس أو تاكروليماس (لمنع رفض الجسم للأعضاء المزروعة)</p><p dir="RTL">&bull; سيكلوفوسفاميد، قلويدات الفينكا (الفينكريستين، فينبلاستين أو الأدوية المشابهة) أدوية تستخدم لعلاج السرطان</p><p dir="RTL">&bull; هالوفانترين (دواء يستخدم لعلاج الملاريا)</p><p dir="RTL">&bull; الأدوية من مجموعة الستاتين (أتورفاستاتين، سيمفاستاتين وفلوفاستاتين أو الأدوية المشابهة) أدوية تستخدم للحد من ارتفاع مستويات الكوليسترول</p><p dir="RTL">&bull; ميثادون (دواء يستخدم لعلاج الآلام)</p><p dir="RTL">&bull; سيليكوكسيب، فلوربيبروفين، نابروكسين، آيبوبروفين، لورنوكسيكام، ميلوكسيكام، ديكلوفيناك (الأدوية غير الستيرويدية المضادة للالتهابات)</p><p dir="RTL">&bull; حبوب منع الحمل الفموية</p><p dir="RTL">&bull; بريدنيزون (الستيرويد)</p><p dir="RTL">&bull; زيدوفودين، المعروف أيضاً باسم AZT، أو ساكوينافير (أدوية تستخدم للمرضى المصابين بفيروس نقص المناعة البشرية المكتسبة)</p><p dir="RTL">&bull; كلوربروباميد، غليبينكلاميد، غليبيزيد أو تولبوتاميد والتي تستخدم للسيطرة على مرض السكري</p><p dir="RTL">&bull; الثيوفيلين (يستخدم للسيطرة على نوبات الربو)</p><p dir="RTL">&bull; توفاسيتينيب (يستخدم لعلاج التهاب المفاصل الروماتويدي)</p><p dir="RTL">&bull; تولفابتان، يستخدم لعلاج نقص صوديوم الدم (انخفاض مستويات الصوديوم في الدم) أو للحد من تدهور وظائف الكلى</p><p dir="RTL">&bull; فيتامين (أ) (أحد المكملات الغذائية)</p><p dir="RTL">&bull; إيفاكفتور (دواء يستخدم لعلاج التليف الكيسي)</p><p dir="RTL">&bull; أميودارون (سواءً كان بمفرده أو بالتزامن مع أدوية أخرى تستخدم لعلاج عدم انتظام ضربات القلب&quot; دقات القلب غير المنتظمة&quot;)</p><p dir="RTL">&bull; هيدروكلوروثيازيد (دواء مدر للبول)</p><p dir="RTL">&bull; إيبروتينيب (يستخدم لعلاج سرطان الدم).</p><p dir="RTL">&bull; لوراسيدون (لعلاج داء الفصام).</p><p dir="RTL"><strong>تناول أوراماكس مع الطعام والشراب</strong></p><p dir="RTL">بإمكانك تناول الكبسولة مع أو بدون تناول وجبة الطعام.</p><p dir="RTL"><strong>الحمل، الرضاعة الطبيعية أو الخصوبة</strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه للحصول على المشورة الطبية قبل تناول هذا الدواء، في حال كنت حاملاً، تعتقدين بأنك حاملاً، تخططين كي تصبحي حاملاً أو ترضعي طفلك رضاعة طبيعية.</p><p dir="RTL">يجب عليك عدم تناول <strong>أوراماكس </strong>إذا كنت حاملاً، تعتقدين أنك حاملاً، تخططين كي تصبحي حاملاً ما لم يخبرك طبيبك بذلك. يرجى منك الاتصال في طبيبك المعالج، في حال كنت قد أصبحت حاملاً أثناء تناول هذا الدواء أو في غضون أسبوع واحد من تناول آخر جرعة من <strong>أوراماكس</strong>.</p><p dir="RTL">يجب عليك عدم تناول<strong> </strong>فلوكونازول<strong> </strong>أثناء الأشهر الثلاثة الأولى من الحمل، حيث أنه قد يؤدي إلى زيادة خطر حدوث الإجهاض. قد يؤدي تناول الفلوكونازول بجرعات منخفضة خلال الأشهر الثلاثة الأولى من الحمل إلى زيادة طفيفة في خطر ولادة طفل مصاب بعيوب خلقية التي تؤثر على العظام و/أو العضلات.</p><p dir="RTL">يمكنك مواصلة الرضاعة الطبيعية بعد تناول جرعة واحدة من <strong>أوراماكس</strong> 150<strong> </strong>ملغم.</p><p dir="RTL">يرجى منك عدم إرضاع طفلك رضاعة طبيعية في حال كنت تكررين تناول جرعات من <strong>أوراماكس</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب <strong>أوراماكس </strong>دوخة أو اختلاجات. يرجى منك عدم القيادة أو استخدام الآلات في حال حدوث ذلك لك.</p><p dir="RTL"><strong>يحتوي أوراماكس على اللاكتوز</strong></p><p dir="RTL">يحتوي هذا الدواء على اللاكتوز. يرجى منك استشارة طبيبك المعالج قبل تناول هذا الدواء،<strong> </strong>إذا كان قد أخبرك مسبقاً بأنك تعاني من مشكلة تتمثل في عدم القدرة على تحمل بعض أنواع السكر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو عليه الحال مع جميع الأدوية، قد يؤدي هذا الدواء في بعض الأحيان إلى حدوث تأثيرات جانبية، على الرغم من ذلك قد لا يحدث ذلك لكل شخص.</p><p dir="RTL">يرجى منك التوقف عن تناول <strong>أوراماكس</strong> وطلب العناية الطبية على الفور، إذا لاحظت أيًا من الأعراض التالية:</p><p dir="RTL">&bull;&nbsp; طفح جلدي واسع الانتشار، ارتفاع درجة حرارة الجسم وتضخم الغدد الليمفاوية (متلازمة دريس أو متلازمة فرط الحساسية الدوائية)</p><p dir="RTL">قد يحدث لدى بعض الأشخاص <strong>تفاعلات تحسسية</strong> على الرغم من ذلك فإن التفاعلات التحسسية الخطيرة نادرة الحدوث.</p><p dir="RTL">يرجى منك التحدث مع طبيبك المعالج أو الصيدلي الذي تتعامل معه، في حال تعرضت لأي من التأثيرات الجانبية بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة . في حال تعرضت لأي من الأعراض التالية، <strong>يرجى منك إخبار طبيبك المعالج على الفور</strong>.&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL">&bull;&nbsp; أزيز مفاجىء، صعوبة في التنفس أو ضيق في الصدر</p><p dir="RTL">&bull;&nbsp; تورم في الجفون، الوجه أو الشفتين</p><p dir="RTL">&bull;&nbsp; حكة في جميع أنحاء الجسم، ظهور بثور أو بقع حمراء على الجلد مصحوبة بحكة</p><p dir="RTL">&bull;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp; تفاعلات جلدية شديدة على سبيل المثال الطفح الجلدي الذي يسبب تقرحات (يمكن أن يؤثر ذلك على الفم واللسان).</p><p dir="RTL">قد يؤثر <strong>أوراماكس</strong> على الكبد. تتضمن الأعراض الدالة على حدوث اضطرابات في الكبد على:</p><p dir="RTL">&bull;&nbsp; الشعور بالإرهاق</p><p dir="RTL">&bull;&nbsp; فقدان الشهية</p><p dir="RTL">&bull;&nbsp; &nbsp;تقيؤ</p><p dir="RTL">&bull;&nbsp; &nbsp;اصفرار لون الجلد وبياض العينين (اليرقان).</p><p dir="RTL">في حال حدوث أي من هذه الأعراض يجب عليك التوقف عن تناول <strong>أوراماكس</strong> <strong>والتواصل مع طبيبك المعالج على الفور.</strong></p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى:</strong></p><p dir="RTL">بالإضافة إلى ذلك، في حال ازدادت خطورة أياً من التأثيرات الجانبية التالية، أو إذا لاحظت حدوث أية تأثيرات جانبية أخرى غير مذكورة في هذه النشرة، يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه.</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص):</strong></p><p dir="RTL">&bull;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp; اضطرابات في المعدة، إسهال، الشعور بالغثيان والتقيؤ</p><p dir="RTL">&bull;&nbsp; ارتفاع في مستويات نتائج اختبارات الدم لوظائف الكبد</p><p dir="RTL">&bull;&nbsp; طفح جلدي</p><p dir="RTL"><strong>التأثيرات الجانبية الغير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص): </strong></p><p dir="RTL">&bull;&nbsp; انخفاض تعداد خلايا الدم الحمراء الذي من الممكن أن يؤدي إلى شحوب لون الجلد والشعور بالضعف أو ضيق في التنفس</p><p dir="RTL">&bull;&nbsp; فقدان الشهية</p><p dir="RTL">&bull;&nbsp; عدم القدرة على النوم، الشعور بالنعاس</p><p dir="RTL">&bull;&nbsp; نوبات تشنجية، دوخة، الشعور بالدوار، وخز أو تنميل، تغيرات في حاسة التذوق</p><p dir="RTL">&bull;&nbsp; إمساك، عسر الهضم، ريح، جفاف الفم</p><p dir="RTL">&bull;&nbsp; ألم في العضلات</p><p dir="RTL">&bull;&nbsp; تلف الكبد واصفرار الجلد والعينين (يرقان)</p><p dir="RTL">&bull;&nbsp; طفح جلدي على شكل خلايا النحل، تقرحات، حكة، زيادة التعرق</p><p dir="RTL">&bull;&nbsp; الشعور بالتعب أو الشعور بالتوعك بصورة عامة، حمى</p><p dir="RTL"><strong>التأثيرات الجانبية النادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص):</strong></p><p dir="RTL">&bull;&nbsp; انخفاض غير طبيعي في خلايا الدم البيضاء التي تساعد في الدفاع عن الجسم ضد العدوى وخلايا الدم التي تساعد على إيقاف النزيف</p><p dir="RTL">&bull;&nbsp; تغير لون الجلد إلى اللون الأحمر أو الأرجواني الذي قد يكون ناجم عن انخفاض تعداد الصفائح الدموية، وغيرها من التغييرات في خلايا الدم</p><p dir="RTL">&bull;&nbsp; تغييرات في كيمياء الدم (ارتفاع الكوليسترول والدهون في الدم)</p><p dir="RTL">&bull;&nbsp; انخفاض مستوى البوتاسيوم في الدم</p><p dir="RTL">&bull;&nbsp; ارتعاش</p><p dir="RTL">&bull;&nbsp; تخطيط كهربائية القلب الغير طبيعي، تغيرات في نظم ضربات القلب</p><p dir="RTL">&bull;&nbsp; فشل الكبد</p><p dir="RTL">&bull;&nbsp; تفاعلات تحسسية (وتكون في بعض الأحيان شديدة)، بما في ذلك الطفح الجلدي المصحوب بظهور تقرحات على نطاق واسع من الجلد وتقشر الجلد، تفاعلات جلدية شديدة، تورم الشفتين أو الوجه</p><p dir="RTL">&bull;&nbsp; تساقط الشعر</p><p dir="RTL"><strong>معدل تكرار حدوثها غير معروفة، ولكنها قد تحدث (لا يمكن تقدير معدل تكرار حدوثها من البيانات المتاحة) </strong></p><p dir="RTL">&bull;&nbsp; تفاعلات فرط الحساسية المصحوبة بحدوث طفح جلدي، حمى، تورم الغدد، زيادة في نوع خلايا الدم البيضاء (فرط الحمضات) والتهاب الأعضاء الداخلية (الكبد، الرئتين، القلب، الكلى والأمعاء الغليظة) (التفاعل الدوائي أو الطفح الجلدي المصحوب بفرط الحمضات والأعراض الجهازية)</p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">يُرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، في حال حدوث أية تأثيرات جانبية بما في ذلك أية تأثيرات جانبية يحتمل حدوثها غير مذكورة في هذه النشرة. كما يمكنك أيضاً الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL">-&nbsp;&nbsp; <strong>مركز الاتصال الموحد:</strong> 19999</p><p dir="RTL">-&nbsp;&nbsp; <strong>البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp; ا<strong>لموقع الإلكتروني:</strong> /https://ade.sfda.gov.sa</p><p dir="RTL">&sect;&nbsp;&nbsp; <strong>دول الخليج العربي الأخرى:</strong></p><p dir="RTL">-&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">- يجب عدم تناول <strong>أوراماكس </strong>بعد تاريخ انتهاء الصلاحية المذكور على العبوة والشريط.</p><p dir="RTL">- يحفظ في درجة حرارة أقل من 30&deg;م.</p><p dir="RTL">- يجب عدم تناول <strong>أوراماكس </strong>إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">- يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي فلوكونازول. تحتوي كل كبسولة على 150 ملغم من فلوكونازول.</p><p dir="RTL">المواد الأخرى: لاكتوز أحادي الهيدرات، نشا الذرة، لوريل سلفات الصوديوم، ثنائي أكسيد السيليكون الغروي، استيارات المغنيسيوم وجيلاتين صلب.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر كبسولات <strong>أوراماكس </strong>في عبوة تحتوي على كبسولة واحدة .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            5/8/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oramax 150mg Capsules 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains:
Item No.	Material Name	Scale (mg/Capsule)
		
	Active Ingredient:	
1.		Fluconazole 	150.00
		
	Inactive Ingredients: 	
1.		Lactose monohydrate (Dense)	153.28
2.		Maize starch (Dried)	  34.00
3.		Sodium lauryl sulphate 	    1.70
4.		Colloidal silicon dioxide (Aerosil 200)	    0.34
5.		Magnesium stearate 	    0.68
6.		Empty hard gelatin capsule size’1’	   1 no.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard Gelatin Capsules 
Description: Hard gelatin self locking capsules, size “1” filled with white to off-white powder.
Color:   Cap: Blue Opaque
              Body: Blue Opaque
Imprinting:   Cap: Julphar
                       Body: Julphar

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fluconazole is indicated in the following fungal infections (see section 5.1).</strong></p><p><u>Fluconazole<strong> </strong></u><u>is indicated in adults for the treatment of:</u></p><p>&sect; Cryptococcal meningitis (see section 4.4).</p><p>&sect; Coccidioidomycosis (see section 4.4).</p><p>&sect; Invasive candidiasis.</p><p>&sect; Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.</p><p>&sect; Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.</p><p>&sect; Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.</p><p>&sect; Candidal balanitis when local therapy is not appropriate.</p><p>&sect; Dermatomycosis including <em>tinea pedis, tinea corporis, tinea cruris, tinea versicolor </em>and dermal <em>candida </em>infections when systemic therapy is indicated.</p><p>&sect; Tinea<em> unguinium (onychomycosis) </em>when other agents are not considered appropriate.</p><p>Fluconazole<strong> </strong>is indicated in adults for the prophylaxis of:</p><p>&sect; Relapse of cryptococcal meningitis in patients with high risk of recurrence.</p><p>&sect; Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.</p><p>&sect; To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).</p><p>&sect; Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation (see section 5.1)).</p><p><u>Fluconazole<strong> </strong></u><u>is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:</u></p><p>Fluconazole<strong> </strong>is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole<strong> </strong>can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence (see section 4.4). Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.</p><p>Consideration should be given to official guidance on the appropriate use of antifungals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>The dose should be based on the nature and severity of the fungal infection. Treatment of infections requiring multiple dosing should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided.</p><p>An inadequate period of treatment may lead to recurrence of active infection.</p><p><strong>Adults</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong><u>Indications</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Posology</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Duration of treatment</u></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Cryptococcosis</strong></p></td><td style="vertical-align:top"><p>- &nbsp;Treatment of cryptococcal meningitis.</p></td><td style="vertical-align:top"><p>Loading dose: 400 mg on Day 1</p><p>Subsequent dose: 200 mg to 400 mg once daily</p></td><td style="vertical-align:top"><p>Usually at least 6 to 8 weeks.</p><p>In life threatening infections the daily dose can be increased to 800 mg</p></td></tr><tr><td style="vertical-align:top"><p>- Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with high risk of recurrence.</p></td><td style="vertical-align:top"><p>200 mg once daily</p></td><td style="vertical-align:top"><p>Indefinitely at a daily dose of 200 mg</p></td></tr><tr><td style="vertical-align:top"><p><strong>Coccidioidomycosis</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>200 mg to 400 mg once daily</p></td><td style="vertical-align:top"><p>11 months up to 24 months or longer depending on the patient. 800 mg daily may be considered for some infections and especially for meningeal disease</p></td></tr><tr><td style="vertical-align:top"><p><strong>Invasive candidiasis</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Loading dose: 800 mg on Day 1</p><p>Subsequent dose: 400 mg once daily</p></td><td style="vertical-align:top"><p>In general, the recommended duration of therapy for candidemia is for 2 weeks after first negative blood culture result and resolution of signs and symptoms attributable to candidemia.</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Treatment of mucosal</strong></p><p><strong>Candidiasis</strong></p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oropharyngeal candidiasis</p></td><td style="vertical-align:top"><p>Loading dose: 200 mg</p><p>to 400 mg on Day 1</p><p>Subsequent dose: 100</p><p>mg to 200 mg once</p><p>daily</p></td><td style="vertical-align:top"><p>7 to 21 days (until oropharyngeal candidiasis is in remission).</p><p>Longer periods may be used in patients with severely</p><p>compromised immune function</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oesophageal candidiasis</p></td><td style="vertical-align:top"><p>Loading dose: 200 mg</p><p>to 400 mg on Day 1</p><p>Subsequent dose: 100</p><p>mg to 200 mg once</p><p>daily</p></td><td style="vertical-align:top"><p>14 to 30 days (until oesophageal candidiasis is in remission).</p><p>Longer periods may be used in patients with severely</p><p>compromised immune function</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Candiduria</p></td><td style="vertical-align:top"><p>200 mg to 400 mg once daily</p></td><td style="vertical-align:top"><p>7 to 21 days. Longer periods may be used in patients with severely compromised immune function.</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic atrophic candidiasis</p></td><td style="vertical-align:top"><p>50 mg once daily</p></td><td style="vertical-align:top"><p>14 days</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic mucocutaneous candidiasis</p></td><td style="vertical-align:top"><p>50 mg to 100 mg once</p><p>daily</p></td><td style="vertical-align:top"><p>Up to 28 days. Longer periods depending on both the severity of infection or underlying immune compromisation and infection</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Prevention of relapse of</strong></p><p><strong>mucosal candidiasis in</strong></p><p><strong>patients infected with HIV</strong></p><p><strong>who are at high risk of</strong></p><p><strong>experiencing relapse</strong></p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oropharyngeal candidiasis</p></td><td style="vertical-align:top"><p>100 mg to 200 mg once daily or 200 mg 3 times per week</p></td><td style="vertical-align:top"><p>An indefinite period for patients</p><p>with chronic immune</p><p>suppression</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oesophageal candidiasis</p></td><td style="vertical-align:top"><p>100 mg to 200 mg once daily or 200 mg 3 times per week</p></td><td style="vertical-align:top"><p>An indefinite period for patients</p><p>with chronic immune</p><p>suppression</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Genital candidiasis</strong></p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp; Acute vaginal candidiasis</p><p>- Candidal balanitis</p></td><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>Single dose</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; Treatment and prophylaxis of recurrent vaginal candidiasis (4 or more episodes a year).</p></td><td style="vertical-align:top"><p>150 mg every third day for a total of 3 doses (day 1, 4, and 7) followed by 150 mg once weekly maintenance dose</p></td><td style="vertical-align:top"><p>Maintenance dose: 6 months.</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Dermatomycosis</strong></p></td><td style="vertical-align:top"><p><em>- tinea pedis,</em></p><p><em>- tinea corporis,</em></p><p><em>- tinea cruris,</em></p><p>-&nbsp;<em>candida&nbsp;</em>infections</p></td><td style="vertical-align:top"><p>150 mg once weekly or 50 mg once daily</p></td><td style="vertical-align:top"><p>2 to 4 weeks,&nbsp;<em>tinea pedis</em>&nbsp;may require treatment for up to 6 weeks</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>- tinea versicolor</em></p></td><td style="vertical-align:top"><p>300 mg to 400 mg once weekly</p></td><td style="vertical-align:top"><p>1 to 3 weeks</p></td></tr><tr><td style="vertical-align:top"><p>50 mg once daily</p></td><td style="vertical-align:top"><p>2 to 4 weeks</p></td></tr><tr><td style="vertical-align:top"><p><em>- tinea unguium</em></p><p><em>(onychomycosis)</em></p></td><td style="vertical-align:top"><p>150 mg once weekly</p></td><td style="vertical-align:top"><p>Treatment should be continued until infected nail is replaced (uninfected nail grows in). Regrowth of fingernails and toenails normally requires 3 to 6 months and 6 to 12 months, respectively. However, growth rates may vary widely in individuals, and by age. After successful treatment of long-term chronic infections, nails occasionally remain disfigured.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prophylaxis of candidal</strong></p><p><strong>infections in patients with prolonged neutropenia</strong></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>200 mg to 400 mg once daily</p></td><td style="vertical-align:top"><p>Treatment should start several days before the anticipated onset of neutropenia and continue for 7 days after recovery from neutropenia after the neutrophil count rises above 1000 cells per mm<sup>3</sup>.</p></td></tr></tbody></table><p><strong><u>Special populations</u></strong></p><p><strong>Elderly</strong></p><p>Dosage should be adjusted based on the renal function (see &ldquo;<em>Renal impairment</em>&rdquo;).</p><p><strong>Renal impairment</strong></p><p>Fluconazole is predominantly excreted in the urine as unchanged active substance. No adjustments in single dose therapy are necessary. In patients (including paediatric population) with impaired renal function who will receive multiple doses of fluconazole, an initial dose of 50 mg to 400 mg should be given, based on the recommended daily dose for the indication. After this initial loading dose, the daily dose (according to indication) should be based on the following table:</p><table border="1" cellspacing="0" cellpadding="0" style="width:564px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Percent of recommended dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;50</p></td><td style="vertical-align:top"><p>100%</p></td></tr><tr><td style="vertical-align:top"><p>&le;50 (no haemodialysis)</p></td><td style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>Haemodialysis</p></td><td style="vertical-align:top"><p>100% after each haemodialysis</p></td></tr></tbody></table><p>Patients on haemodialysis should receive 100% of the recommended dose after each haemodialysis; on non-dialysis days, patients should receive a reduced dose according to their creatinine clearance.</p><p><strong>Hepatic impairment</strong></p><p>Limited data are available in patients with hepatic impairment, therefore fluconazole should be administered with caution to patients with liver dysfunction (see sections 4.4 and 4.8).</p><p><strong>Paediatric population</strong></p><p>A maximum dose of 400 mg daily should not be exceeded in paediatric population.</p><p>As with similar infections in adults, the duration of treatment is based on the clinical and mycological response. Fluconazole is administered as a single daily dose.</p><p>For paediatric patients with impaired renal function, see dosing in &ldquo;<em>Renal impairment</em>&rdquo;. The pharmacokinetics of fluconazole has not been studied in paediatric population with renal insufficiency (for &ldquo;Term newborn infants&rdquo; who often exhibit primarily renal immaturity please see below).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Infants, toddlers and children (from 28 days to 11 years old):</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Indication</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Posology</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Recommendations</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>- Mucosal candidiasis</p></td><td style="vertical-align:top"><p>Initial dose: 6 mg/kg</p><p>Subsequent dose: 3 mg/kg once daily</p></td><td style="vertical-align:top"><p>Initial dose may be used on the first day to achieve steady state levels more rapidly</p></td></tr><tr><td style="vertical-align:top"><p>- Invasive candidiasis</p><p>- Cryptococcal meningitis</p></td><td style="vertical-align:top"><p>Dose: 6 to 12 mg/kg once daily</p></td><td style="vertical-align:top"><p>Depending on the severity of the disease</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; Maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of recurrence</p></td><td style="vertical-align:top"><p>Dose: 6 mg/kg once daily</p></td><td style="vertical-align:top"><p>Depending on the severity of the disease</p></td></tr><tr><td style="vertical-align:top"><p>- Prophylaxis of <em>Candida </em>in immunocompromised patients</p></td><td style="vertical-align:top"><p>Dose: 3 to 12 mg/kg once daily</p></td><td style="vertical-align:top"><p>Depending on the extent and duration of the induced neutropenia (see Adults</p><p>posology)</p></td></tr></tbody></table><p><u>Adolescents (from 12 to 17 years old):</u></p><p>Depending on the weight and pubertal development, the prescriber would need to assess which posology (adults or children) is the most appropriate. Clinical data indicate that children have a higher fluconazole clearance than observed for adults. A dose of 100, 200 and 400 mg in adults corresponds to a 3, 6 and 12 mg/kg dose in children to obtain a comparable systemic exposure.</p><p>Safety and efficacy for genital candidiasis indication in paediatric population has not been established. Current available safety data for other paediatric indications are described in section 4.8. If treatment for genital candidiasis is imperative in adolescents (from 12 to 17 years old), the posology should be the same as adults posology.</p><p><u>Term newborn infants (0 to 27 days):</u></p><p>Neonates excrete fluconazole slowly. There are few pharmacokinetic data to support this posology in term newborn infants (see section 5.2).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Age group</strong></p></td><td style="vertical-align:top"><p><strong>Posology</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Term newborn infants (0 to 14 days)</p></td><td style="vertical-align:top"><p>The same mg/kg dose as for infants, toddlers and children should be given every 72 hours</p></td><td style="vertical-align:top"><p>A maximum dose of 12 mg/kg every 72 hours should not be exceeded</p></td></tr><tr><td style="vertical-align:top"><p>Term newborn infants (from 15 to 27 days)</p></td><td style="vertical-align:top"><p>The same mg/kg dose as for infants, toddlers and children should be given every 48 hours</p></td><td style="vertical-align:top"><p>A maximum dose of 12 mg/kg every 48 hours should not be exceeded</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Method of administration</u></strong></p><p>Fluconazole may be administered either orally (Capsules and Powder for Oral Suspension) or by intravenous infusion (Solution for Infusion), the route being dependent on the clinical state of the patient. On transferring from the intravenous to the oral route, or vice versa, there is no need to change the daily dose.</p><p>The physician should prescribe the most appropriate pharmaceutical form and strength according to age, weight and dose. The capsule formulation is not adapted for use in infants and small children. Oral liquid formulations of fluconazole are available that are more suitable in this population.</p><p>The capsules should be swallowed whole and independent of food intake</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to related azole substances, or to any of the excipients listed in section 6.1.
Co-administration of terfenadine is contraindicated in patients receiving fluconazole at multiple doses of 400 mg per day or higher based upon results of a multiple dose interaction study.      Co-administration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 such as cisapride, astemizole, pimozide, quinidine, and erythromycin are contraindicated in patients receiving fluconazole (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Tinea capitis</u></strong></p><p>Fluconazole has been studied for treatment of&nbsp;<em>tinea capitis</em>&nbsp;in children. It was shown not to be superior to griseofulvin and the overall success rate was less than 20%. Therefore, fluconazole should not be used for&nbsp;<em>tinea capitis.</em></p><p><strong><u>Cryptococcosis</u></strong></p><p>The evidence for efficacy of fluconazole in the treatment of cryptococcosis of other sites (e.g. pulmonary and cutaneous cryptococcosis) is limited, which prevents dosing recommendations.</p><p><strong><u>Deep endemic mycoses</u></strong></p><p>The evidence for efficacy of fluconazole in the treatment of other forms of endemic mycoses such as&nbsp;<em>paracoccidioidomycosis, lymphocutaneous sporotrichosis</em>&nbsp;and&nbsp;<em>histoplasmosis</em>&nbsp;is limited, which prevents specific dosing recommendations.</p><p><strong><u>Renal system</u></strong></p><p>Fluconazole should be administered with caution to patients with renal dysfunction (see section 4.2).</p><p><strong><u>Adrenal insufficiency</u></strong></p><p>Ketoconazole is known to cause adrenal insufficiency, and this could also although rarely seen be applicable to fluconazole. Adrenal insufficiency relating to concomitant treatment with prednisone, see section 4.5<strong>&nbsp;&#39;The effect of fluconazole on other medicinal products&#39;</strong>.</p><p><strong><u>Hepatobiliary system </u></strong></p><p>Fluconazole should be administered with caution to patients with liver dysfunction.</p><p>Fluconazole has been associated with rare cases of serious hepatic toxicity including fatalities, primarily in patients with serious underlying medical conditions. In cases of fluconazole associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex or age of patient has been observed. Fluconazole hepatotoxicity has usually been reversible on discontinuation of therapy.</p><p>Patients who develop abnormal liver function tests during fluconazole therapy must be monitored closely for the development of more serious hepatic injury.</p><p>The patient should be informed of suggestive symptoms of serious hepatic effect (important asthenia, anorexia, persistent nausea, vomiting and jaundice). Treatment of fluconazole should be immediately discontinued and the patient should consult a physician.</p><p><strong><u>Cardiovascular system</u></strong></p><p>Some azoles, including fluconazole, have been associated with prolongation of the QT interval on the electrocardiogram. Fluconazole causes QT prolongation via the inhibition of Rectifier Potassium Channel current (I<sub>kr</sub>). The QT prolongation caused by other medicinal products (such as amiodarone) may be amplified via the inhibition of cytochrome P450 (CYP) 3A4. During post-marketing surveillance, there have been very rare cases of QT prolongation and&nbsp;<em>torsades de pointes</em>&nbsp;in patients taking fluconazole. These reports included seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities and concomitant treatment that may have been contributory. Patients with hypokalaemia and advanced cardiac failure are at an increased risk for the occurrence of life threatening ventricular arrhythmias and&nbsp;<em>torsades de pointes</em>.</p><p>Fluconazole should be administered with caution to patients with potentially proarrhythmic conditions.</p><p>Co-administration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 are contraindicated (see sections 4.3 and 4.5).</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Halofantrine</u></strong></p><p>Halofantrine has been shown to prolong QTc interval at the recommended therapeutic dose and is a substrate of CYP3A4. The concomitant use of fluconazole and halofantrine is therefore not recommended (see section 4.5).</p><p><strong><u>Dermatological reactions</u></strong></p><p>Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported. &nbsp;AIDS patients are more prone to the development of severe cutaneous reactions to many medicinal products. If a rash, which is considered attributable to fluconazole, develops in a patient treated for a superficial fungal infection, further therapy with this medicinal product should be discontinued. If patients with invasive/systemic fungal infections develop rashes, they should be monitored closely, and fluconazole discontinued if bullous lesions or erythema multiforme develop.</p><p><strong><u>Hypersensitivity</u></strong></p><p>In rare cases anaphylaxis has been reported (see section 4.3).</p><p><strong><u>Cytochrome P450</u></strong></p><p>Fluconazole is a moderate CYP2C9 and CYP3A4 inhibitor. Fluconazole is also a strong inhibitor of CYP2C19. Fluconazole treated patients who are concomitantly treated with medicinal products with a narrow therapeutic window metabolised through CYP2C9, CYP2C19 and CYP3A4, should be monitored (see section 4.5).</p><p><strong><u>Terfenadine</u></strong></p><p>The co-administration of fluconazole at doses lower than 400 mg per day with terfenadine should be carefully monitored (see sections 4.3 and 4.5).</p><p><strong><u>Candidiasis</u></strong></p><p>Studies have shown an increasing prevalence of infections with Candida species other than C. albicans. These are often inherently resistant (e.g. C. krusei and C. auris) or show reduced susceptibility to fluconazole (C. glabrata). Such infections may require alternative antifungal therapy secondary to treatment failure. Therefore, prescribers are advised to take into account the prevalence of resistance in various Candida species to fluconazole.</p><p><strong><u>Excipients</u></strong></p><p><strong>Oramax</strong> Capsules contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Concomitant use of the following other medicinal products are contraindicated:</u></strong></p><p><strong>Cisapride:</strong> There have been reports of cardiac events including <em>torsades de pointes </em>in patients to whom fluconazole and cisapride were co-administered. A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval. Concomitant treatment with fluconazole and cisapride is contraindicated (see section 4.3).</p><p><strong>Terfenadine:</strong> Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a 200 mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400 mg and 800 mg daily dose of fluconazole demonstrated that fluconazole taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated (see section 4.3). The co-administration of fluconazole at doses lower than 400 mg per day with terfenadine should be carefully monitored.</p><p><strong>Astemizole:</strong> Concomitant administration of fluconazole with astemizole may decrease the clearance of astemizole. Resulting increased plasma concentrations of astemizole can lead to QT prolongation and rare occurrences of <em>torsades</em><em> </em><em>de pointes</em>. Co-administration of fluconazole and astemizole is contraindicated (see section 4.3).</p><p><strong>Pimozide:</strong> Although not studied <em>in vitro </em>or <em>in vivo</em>, concomitant administration of fluconazole with pimozide may result in inhibition of pimozide metabolism. Increased pimozide plasma concentrations can lead to QT prolongation and rare occurrences of <em>torsades de pointes</em>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Co-administration of fluconazole and pimozide is contraindicated (see section 4.3).</p><p><strong>Quinidine:</strong> Although not studied <em>in vitro </em>or <em>in vivo</em>, concomitant administration of fluconazole with quinidine may result in inhibition of quinidine metabolism. Use of quinidine has been associated with QT prolongation and rare occurrences of <em>torsades de pointes</em>. Co-administration of fluconazole and quinidine is contraindicated (see section 4.3).</p><p><strong>Erythromycin:</strong> Concomitant use of fluconazole and erythromycin has the potential to increase the risk of cardiotoxicity (prolonged QT interval, <em>torsades de pointes</em>) and consequently sudden heart death. Co-administration of fluconazole and erythromycin is contraindicated (see section 4.3).</p><p><strong><u>Concomitant use of the following other medicinal products cannot be recommended:</u></strong></p><p><strong>Halofantrine:</strong> Fluconazole can increase halofantrine plasma concentration due to an inhibitory effect on CYP3A4. Concomitant use of fluconazole and halofantrine has the potential to increase the risk of cardiotoxicity (prolonged QT interval, <em>torsades de pointes</em>) and consequently sudden heart death. This combination should be avoided (see section 4.4).</p><p><strong><u>Concomitant use that should be used with caution:</u></strong></p><p><strong>Amiodarone:</strong> Concomitant administration of fluconazole with amiodarone may increase QT prolongation. Caution must be exercised if the concomitant use of fluconazole and amiodarone is necessary, notably with high dose fluconazole (800 mg).</p><p><strong><u>Concomitant use of the following other medicinal products lead to precautions and dose adjustments:</u></strong></p><p><u>The effect of other medicinal products on fluconazole</u></p><p><strong>Rifampicin:</strong> Concomitant administration of fluconazole and rifampicin resulted in a 25% decrease in the <em>AUC </em>and a 20% shorter half-life of fluconazole. In patients receiving concomitant rifampicin, an increase of the fluconazole dose should be considered.</p><p>Interaction studies have shown that when oral fluconazole is co-administered with food, cimetidine, antacids or following total body irradiation for bone marrow transplantation, no clinically significant impairment of fluconazole absorption occurs.</p><p><strong>Hydrochlorothiazide:</strong> In a pharmacokinetic interaction study, co-administration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentration of fluconazole by 40%. An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics.</p><p><strong><u>The effect of fluconazole on other medicinal products</u></strong></p><p>Fluconazole is a moderate inhibitor of cytochrome P450 (CYP) isoenzymes 2C9 and 3A4. Fluconazole is also a strong inhibitor of the isozyme CYP2C19. In addition to the observed/documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolised by CYP2C9, CYP2C19 and CYP3A4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; co-administered with fluconazole. Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored. The enzyme inhibiting effect of fluconazole persists 4-5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole (see section 4.3).</p><p><strong>Alfentanil:</strong> During concomitant treatment with fluconazole (400 mg) and intravenous alfentanil (20 &mu;g/kg) in healthy volunteers the alfentanil AUC 10 increased 2-fold, probably through inhibition of CYP3A4.Dose adjustment of alfentanil may be necessary.</p><p><strong>Amitriptyline, nortriptyline:</strong> Fluconazole increases the effect of amitriptyline and nortriptyline. 5-nortriptyline and/or Samitriptyline may be measured at initiation of the combination therapy and after one week. Dose of amitriptyline/nortriptyline should be adjusted, if necessary.</p><p><strong>Amphotericin B:</strong> Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic infection with <em>C. albicans</em>, no interaction in intracranial infection with <em>Cryptococcus neoformans</em>, and antagonism of the two medicinal products in systemic infection with <em>Aspergillus fumigatus</em>. The clinical significance of results obtained in these studies is unknown.</p><p><strong>Anticoagulants:</strong> In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, haematuria, and melena) have been reported, in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. During concomitant treatment with fluconazole and warfarin the prothrombin time was prolonged up to 2-fold, probably due to an inhibition of the warfarin metabolism through CYP2C9. In patients receiving coumarin-type or indanedione anticoagulants concurrently with fluconazole the prothrombin time should be carefully monitored. Dose adjustment of the anticoagulant may be necessary.</p><p><strong>Benzodiazepines (short acting), i.e. midazolam, triazolam: </strong>Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. Concomitant intake of fluconazole 200 mg and midazolam 7.5 mg orally increased the midazolam AUC and half-life 3.7-fold and 2.2-fold, respectively. Fluconazole 200 mg daily given concurrently with triazolam 0.25 mg orally increased the triazolam AUC and half-life 4.4-fold and 2.3-fold, respectively. Potentiated and prolonged effects of triazolam have been observed at concomitant treatment with fluconazole. If concomitant benzodiazepine therapy is necessary in patients being treated with fluconazole, consideration should be given to decreasing the benzodiazepine dose, and the patients should be appropriately monitored.</p><p><strong>Carbamazepine:</strong> Fluconazole inhibits the metabolism of carbamazepine and an increase in serum carbamazepine of 30% has been observed. There is a risk of developing carbamazepine toxicity. Dose adjustment of carbamazepine may be necessary depending on concentration measurements/effect.</p><p><strong>Calcium channel blockers: </strong>Certain calcium channel antagonists (nifedipine, isrardipine, amlodipine, verapamil and felodipine) are metabolised by CYP3A4. Fluconazole has the potential to increase the systemic exposure of the calcium channel antagonists. Frequent monitoring for adverse events is recommended.</p><p><strong>Celecoxib: </strong>During concomitant treatment with fluconazole (200 mg daily) and celecoxib (200 mg) the celecoxib C<sub>max</sub> and AUC increased by 68% and 134%, respectively. Half of the celecoxib dose may be necessary when combined with fluconazole.</p><p><strong>Cyclophosphamide:</strong> Combination therapy with cyclophosphamide and fluconazole results in an increase in serum bilirubin and serum creatinine. The combination may be used while taking increased consideration to the risk of increased serum bilirubin and serum creatinine.</p><p><strong>Fentanyl: </strong>One fatal case of fentanyl intoxication due to possible fentanyl fluconazole interaction was reported.</p><p>Furthermore, it was shown in healthy volunteers that fluconazole delayed the elimination of fentanyl significantly.</p><p>Elevated fentanyl concentration may lead to respiratory depression. Patients should be monitored closely for the potential risk of respiratory depression. Dosage adjustment of fentanyl may be necessary.</p><p><strong>HMG CoA reductase inhibitors: </strong>The risk of myopathy and rhabdomyolysis increases (dose-dependent) when fluconazole is co-administered with HMG-CoA reductase inhibitors metabolised through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin (decreased hepatic metabolism of the statin). If concomitant therapy is necessary, the patient should be observed for symptoms of myopathy and rhabdomyolysis and creatine kinase should be monitored. HMG-CoA reductase inhibitors should be discontinued if a marked increase in creatine kinase is observed or myopathy/rhabdomyolysis is diagnosed or suspected. Lower doses of HMG-CoA reductase inhibitors may be necessary as instructed in the statins prescribing information.</p><p><strong>Ibrutinib:</strong> Moderate inhibitors of CYP3A4 such as fluconazole increase plasma ibrutinib concentrations and may increaserisk of toxicity. If the combination cannot be avoided, reduce the dose of ibrutinib to 280 mg once daily (two capsules) forthe duration of the inhibitor use and provide close clinical monitoring.</p><p><strong>Ivacaftor (alone or combined with drugs in the same therapeutic class):</strong> Co-administration with ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, increased ivacaftor exposure by 3-fold and hydroxymethyl-ivacaftor (M1) exposure by 1.9-fold. A reduction of the ivacaftor (alone or combined) dose is necessary as instructed in the ivacaftor (alone or combined) prescribing information.</p><p><strong>Olaparib:</strong> Moderate inhibitors of CYP3A4 such as fluconazole increase olaparib plasma concentrations; concomitant use is not recommended. If the combination cannot be avoided, limit the dose of olaparib to 200 mg twice daily.</p><p><strong><u>Immunosuppresors (i.e. ciclosporin, everolimus, sirolimus and tacrolimus):</u></strong></p><p><strong>Ciclosporin:</strong> Fluconazole significantly increases the concentration and AUC of ciclosporin. During concomitant treatment with fluconazole 200 mg daily and ciclosporin (2.7 mg/kg/day) there was a 1.8-fold increase in ciclosporin AUC. This combination may be used by reducing the dose of ciclosporin depending on ciclosporin concentration.</p><p><strong>Everolimus:</strong> Although not studied <em>in vivo </em>or <em>in vitro</em>, fluconazole may increase serum concentrations of everolimus through inhibition of CYP3A4.</p><p><strong>Sirolimus:</strong> Fluconazole increases plasma concentrations of sirolimus presumably by inhibiting the metabolism of sirolimus via CYP3A4 and P-glycoprotein. This combination may be used with a dose adjustment of sirolimus depending on the effect/concentration measurements.</p><p><strong>Tacrolimus</strong>: Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5 times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines. No significant pharmacokinetic changes have been observed when tacrolimus is given intravenously. Increased tacrolimus levels have been associated with nephrotoxicity.</p><p>Dose of orally administered tacrolimus should be decreased depending on tacrolimus concentration.</p><p><strong>Losartan:</strong> Fluconazole inhibits the metabolism of losartan to its active metabolite (E-31 74) which is responsible for most of the angiotensin II-receptor antagonism which occurs during treatment with losartan. Patients should have their blood pressure monitored continuously.</p><p><strong>Lurasidone:</strong> Moderate inhibitors of CYP3A4 such as fluconazole may increase lurasidone plasma concentrations. If concomitant use cannot be avoided, reduce the dose of lurasidone as instructed in the lurasidone prescribing information.</p><p><strong>Methadone:</strong> Fluconazole may enhance the serum concentration of methadone. Dose adjustment of methadone may be necessary.</p><p><strong>Non-steroidal anti-inflammatory drugs</strong>: The C<sub>max</sub> and AUC of flurbiprofen was increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. Similarly, the C<sub>max</sub> and AUC of the pharmacologically active isomer &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[S-(+)-ibuprofen] was increased by 15% and 82%, respectively, when fluconazole was coadministered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone.</p><p>Although not specifically studied, fluconazole has the potential to increase the systemic exposure of other NSAIDs that are metabolised by CYP2C9 (e.g. naproxen, lornoxicam, meloxicam, diclofenac). Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended. Adjustment of dose of NSAIDs may be needed.</p><p><strong>Phenytoin:</strong> Fluconazole inhibits the hepatic metabolism of phenytoin. Concomitant repeated administration of 200 mg fluconazole and 250 mg phenytoin intravenously, caused an increase of the phenytoin AUC24 by 75% and Cmin by 128%. With co-administration, serum phenytoin concentration levels should be monitored in order to avoid phenytoin toxicity.</p><p><strong>Prednisone:</strong> There was a case report that a liver-transplanted patient treated with prednisone developed acute adrenal cortex insufficiency when a three month therapy with fluconazole was discontinued. The discontinuation of fluconazole presumably caused an enhanced CYP3A4 activity which led to increased metabolism of prednisone. Patients on longterm treatment with fluconazole and prednisone should be carefully monitored for adrenal cortex insufficiency when fluconazole is discontinued.</p><p><strong>Rifabutin:</strong> Fluconazole increases serum concentrations of rifabutin, leading to increase in the AUC of rifabutin up to 80%. There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. In combination therapy, symptoms of rifabutin toxicity should be taken into consideration.</p><p><strong>Saquinavir:</strong> Fluconazole increases the AUC and C<sub>max</sub> of saquinavir with approximately 50% and 55% respectively, due to inhibition of saquinavir&#39;s hepatic metabolism by CYP3A4 and inhibition of P-glycoprotein. Interaction with saquinavir/ritonavir has not been studied and might be more marked. Dose adjustment of saquinavir may be necessary.</p><p><strong>Sulfonylureas: </strong>Fluconazole has been shown to prolong the serum half-life of concomitantly administered oral sulfonylureas (e.g., chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy volunteers. Frequent monitoring of blood glucose and appropriate reduction of sulfonylurea dose is recommended during co-administration.</p><p><strong>Theophylline: </strong>In a placebo controlled interaction study, the administration of fluconazole 200 mg for 14 days resulted in an 18% decrease in the mean plasma clearance rate of theophylline. Patients who are receiving high dose theophylline or who are otherwise at increased risk for theophylline toxicity should be observed for signs of theophylline toxicity while receiving fluconazole. Therapy should be modified if signs of toxicity develop.</p><p><strong>Tofacitinib:</strong> Exposure of tofacitinib is increased when tofacitinib is co-administered with medications that result in both moderate inhibition of CYP3A4 and strong inhibition of CYP2C19 (e.g., fluconazole). Therefore, it is recommended to reduce tofacitinib dose to 5 mg once daily when it is combined with these drugs.</p><p><strong>Tolvaptan: </strong>Exposure to tolvaptan is significantly increased (200% in AUC; 80% in Cmax) when tolvaptan, a CYP3A4substrate, is co-administered with fluconazole, a moderate CYP3A4 inhibitor, with risk of significant increase in adverse reactions particularly significant diuresis, dehydration and acute renal failure. In case of concomitant use, the tolvaptan dose should be reduced as instructed in the tolvaptan prescribing information and the patient should be frequently monitored for any adverse reactions associated with tolvaptan.</p><p><strong>Vinca alkaloids</strong>: Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g. vincristine and vinblastine) and lead to neurotoxicity, which is possibly due to an inhibitory effect on CYP3A4.</p><p><strong>Vitamin A:</strong> Based on a case-report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, CNS related undesirable effects have developed in the form of pseudotumour <em>cerebri</em>, which disappeared after discontinuation of fluconazole treatment. This combination may be used but the incidence of CNS related undesirable effects should be borne in mind.</p><p><strong>Voriconazole:</strong> (CYP2C9, CYP2C19 and CYP3A4 inhibitor): Co-administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 2.5 days) and oral fluconazole (400 mg on day 1, then 200 mg Q24h for 4 days) to 8 healthy male subjects resulted in an increase in C<sub>max</sub> and AUC of voriconazole by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole associated adverse events is recommended if voriconazole is used sequentially after fluconazole.</p><p><strong>Zidovudine:</strong> Fluconazole increases C<sub>max</sub> and AUC of zidovudine by 84% and 74%, respectively, due to an approx. 45% decrease in oral zidovudine clearance. The half-life of zidovudine was likewise prolonged by approximately 128% following combination therapy with fluconazole. Patients receiving this combination should be monitored for the development of zidovudine-related adverse reactions. Dose reduction of zidovudine may be considered.</p><p><strong>Azithromycin:</strong> An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 1200 mg oral dose of azithromycin on the pharmacokinetics of a single 800 mg oral dose of fluconazole as well as the effects of fluconazole on the pharmacokinetics of azithromycin. There was no significant pharmacokinetic interaction between fluconazole and azithromycin.</p><p><strong>Oral contraceptives: </strong>Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. There were no relevant effects on hormone level in the 50 mg fluconazole study, while at 200 mg daily, the AUCs of ethinyl estradiol and levonorgestrel were increased 40% and 24%, respectively. Thus, multiple dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>An observational study has suggested an increased risk of spontaneous abortion in women treated with fluconazole during the first trimester.</p><p>Data from several thousand pregnant women treated with a cumulative dose of &le; 150 mg of fluconazole, administered in the first trimester, show no increase in the overall risk of malformations in the foetus. In one large observational cohort study, first trimester exposure to oral fluconazole was associated with a small increased risk of musculoskeletal malformations, corresponding to approximately 1 additional case per 1000 women treated with cumulative doses &le; 450 mg compared with women treated with topical azoles and to approximately 4 additional cases per 1000 women treated with cumulative doses over 450 mg. The adjusted relative risk was 1.29 (95% CI 1.05 to 1.58) for 150 mg oral fluconazole and 1.98 (95% CI 1.23 to 3.17) for doses over 450 mg fluconazole.</p><p>There have been reports of multiple congenital abnormalities (including brachycephalia, ears dysplasia, giant anterior fontanelle, femoral bowing and radio-humeral synostosis) in infants whose mothers were treated for at least three or more months with high doses (400 - 800 mg daily) of fluconazole for coccidioidomycosis. The relationship between fluconazole use and these events is unclear.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Before becoming pregnant a washout period of approximately 1 week (corresponding to 5-6 half-lives) is recommended after a single-dose or discontinuation of a course of treatment (see section 5.2).</p><p>Fluconazole in standard doses and short-term treatments should not be used in pregnancy unless clearly necessary.</p><p>Fluconazole in high dose and/or in prolonged regimens should not be used during pregnancy except for potentially life threatening infections.</p><p><strong><u>Breast-feeding</u></strong></p><p>Fluconazole passes into breast milk to reach concentrations similar to those in plasma (see section 5.2). Breast-feeding may be maintained after a single dose of 150 mg fluconazole. Breast-feeding is not recommended after repeated use or after high dose fluconazole. The developmental and health benefits of breast-feeding should be considered along with the mother&#39;s clinical need for fluconazole and any potential adverse effects on the breast-fed child from fluconazole or from the underlying maternal condition.</p><p><strong><u>Fertility</u></strong></p><p>Fluconazole did not affect the fertility of male or female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been performed on the effects of Fluconazole on the ability to drive or use machines.</p><p>Patients should be warned about the potential for dizziness or seizures (see section 4.8) while taking Fluconazole and should be advised not to drive or operate machines if any of these symptoms occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in association with fluconazole treatment (see section 4.4).</p><p>The most frequently (&ge;1/100 to &lt;1/10) reported adverse reactions are headache, abdominal pain, diarrhoea, nausea, vomiting, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased and rash.</p><p>The following adverse reactions have been observed and reported during treatment with fluconazole with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Agranulocytosis, leukopenia, thrombocytopenia, neutropenia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylaxis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Hypercholesterolaemia, hypertriglyceridaemia, hypokalaemia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Somnolence, insomnia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Seizures, paraesthesia, dizziness, taste perversion</p></td><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Torsade de pointes (see section 4.4), QT prolongation (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Abdominal pain, vomiting, diarrhoea, nausea</p></td><td style="vertical-align:top"><p>Constipation dyspepsia, flatulence, dry mouth</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased (see section 4.4), aspartate aminotransferase increased (see section 4.4), blood alkaline phosphatase increased (see section 4.4)</p></td><td style="vertical-align:top"><p>Cholestasis (see section 4.4), jaundice (see section 4.4), bilirubin increased (see section 4.4)</p></td><td style="vertical-align:top"><p>Hepatic failure (see section 4.4), hepatocellular necrosis (see section 4.4), hepatitis (see section 4.4), hepatocellular damage (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Rash (see section 4.4)</p></td><td style="vertical-align:top"><p>Drug eruption* (see section 4.4), urticaria (see section 4.4), pruritus, increased sweating</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, (see section 4.4), Stevens-Johnson syndrome (see section 4.4), acute generalised exanthematous-pustulosis (see section 4.4), dermatitis exfoliative, angioedema, face oedema, alopecia</p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Fatigue, malaise, asthenia, fever</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>* including Fixed Drug Eruption</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Paediatric population</u></strong></p><p>The pattern and incidence of adverse reactions and laboratory abnormalities recorded during paediatric clinical trials, excluding the genital candidiasis indication, are comparable to those seen in adults.</p><p>&nbsp;</p><p><strong><u>To report any side effect(s):</u></strong></p><p>&sect; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other GCC States: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been reports of overdose with fluconazole. Hallucination and paranoid behaviour have been concomitantly reported.</p><p>In the event of overdose, symptomatic treatment (with supportive measures and gastric lavage if necessary) may be adequate.</p><p>Fluconazole is largely excreted in the urine; forced volume diuresis would probably increase the elimination rate. A three hour haemodialysis session decreases plasma levels by approximately 50%.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Antimycotics for systemic use, triazole derivatives, ATC code: J02AC01.</p><p><strong><u>Mechanism of action</u></strong></p><p>Fluconazole is a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P-450- mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.</p><p>Fluconazole 50 mg daily given up to 28 days has been shown not to effect testosterone plasma concentrations in males or steroid concentration in females of child-bearing age. Fluconazole 200 mg to 400 mg daily has no clinically significant effect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50 mg do not affect its metabolism.</p><p><strong><u>Susceptibility </u></strong><strong><em><u>in vitro:</u></em></strong></p><p>In vitro, fluconazole displays antifungal activity against clinically common Candida species (including C. albicans, C.parapsilosis, C. tropicalis). C. glabrata shows reduced susceptibility to fluconazole while C. krusei and C. auris areresistant to fluconazole. The MICs and epidemiological cut-off value (ECOFF) of fluconazole for C. guilliermondii arehigher than for C. albicans.</p><p>Fluconazole also exhibits activity in vitro against Cryptococcus neoformans and Cryptococcus. gattii as well as theendemic moulds Blastomyces dermatiditis, Coccidioides immitis, Histoplasma capsulatum and Paracoccidioidesbrasiliensis.</p><p><strong><u>Pharmacokinetic/pharmacodynamic relationship</u></strong></p><p>In animal studies, there is a correlation between MIC values and efficacy against experimental mycoses due to <em>Candida </em>spp. In clinical studies, there is an almost 1:1 linear relationship between the AUC and the dose of fluconazole. There is also a direct though imperfect relationship between the AUC or dose and a successful clinical response of oral<em> </em>candidosis and to a lesser extent candidaemia to treatment. Similarly cure is less likely for infections caused by strains with a higher fluconazole MIC.</p><p><strong><u>Mechanisms of resistance</u></strong></p><p><em>Candida </em>spp have developed a number of resistance mechanisms to azole antifungal agents. Fungal strains which have developed one or more of these resistance mechanisms are known to exhibit high minimum inhibitory concentrations (MICs) to fluconazole which impacts adversely efficacy <em>in vivo </em>and clinically.</p><p>In usually susceptible species of <em>Candida</em>, the most commonly encountered mechanism of resistance development involves the target enzymes of the azoles, which are responsible for the biosynthesis of ergosterol. Resistance may be caused by mutation, increased production of an enzyme, drug efflux mechanisms, or the development of compensatory pathways.</p><p>There have been reports of superinfection with <em>Candida </em>species other than <em>C. albicans</em>, which often have inherently reduced susceptibility (<em>C. glabrata</em>) or resistance to fluconazole (e.g. <em>C. krusei, C. auris</em>). Such infections may require alternative antifungal therapy. The resistance mechanisms have not been completely elucidated in some intrinsically resistant (<em>C. krusei</em>) or emerging (<em>C. auris</em>) species of Candida.<strong><u> </u></strong></p><p><strong><u>EUCAST Breakpoints </u></strong></p><p>Based on analyses of pharmacokinetic/pharmacodynamic (PK/PD) data, susceptibility in vitro and clinical response EUCAST-AFST (European Committee on Antimicrobial Susceptibility Testing-Subcommitte on Antifungal Susceptibility Testing) has determined breakpoints for fluconazole for Candida species (EUCAST Fluconazole rationale document(2020)-version 3; European Committee on Antimicrobial Susceptibility Testing, Antifungal Agents, Breakpoint tables for interpretation of MICs, Version 10.0, valid from 2020-02-04). These have been divided into non-species related breakpoints; which have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species, and species related breakpoints for those species most frequently associated with human infection. These breakpoints are given in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:633px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Antifungal</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Species-related breakpoints (S&le;/R&gt;) in mg/L</strong></p></td><td style="vertical-align:top"><p><strong>Non-species related</strong></p><p><strong>breakpoints<sup>A</sup></strong></p><p><strong>S&le;/R&gt;</strong><strong> in mg/L</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Candida</em></p><p><em>albicans</em></p></td><td style="vertical-align:top"><p><em>Candida</em></p><p><em>dubliniensis</em></p></td><td style="vertical-align:top"><p><em>Candida</em></p><p><em>glabrata</em></p></td><td style="vertical-align:top"><p><em>Candida</em></p><p><em>krusei</em></p></td><td style="vertical-align:top"><p><em>Candida</em></p><p><em>parapsilosis</em></p></td><td style="vertical-align:top"><p><em>Candida</em></p><p><em>tropicalis</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole</p></td><td style="vertical-align:top"><p>2/4</p></td><td style="vertical-align:top"><p>2/4</p></td><td style="vertical-align:top"><p>0.001*/16</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>2/4</p></td><td style="vertical-align:top"><p>2/4</p></td><td style="vertical-align:top"><p>2/4</p></td></tr></tbody></table><p>&nbsp;</p><p>S = Susceptible, R = Resistant</p><p>A = Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent ofMIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints.</p><p>-- = Susceptibility testing not recommended as the species is a poor target for therapy with the medicinal product.</p><p>* = The entire C. glabrata is in the &nbsp;I category. MICs against C. glabrata should be interpreted as resistant when above 16mg/L. Susceptible category (&le;0.001 mg/L) is simply to avoid misclassification of &quot;I&quot; strains as &quot;S&quot; strains. I - Susceptible,increased exposure: A microorganism is categorised as Susceptible, increased exposure when there is a high likelihoodof therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by itsconcentration at the site of infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral route.</p><p><strong><u>Absorption</u></strong></p><p>After oral administration fluconazole is well absorbed, and plasma levels (and systemic bioavailability) are over 90% of the levels achieved after intravenous administration. Oral absorption is not affected by concomitant food intake. Peak plasma concentrations in the fasting state occur between 0.5 and 1.5 hours post-dose. Plasma concentrations are proportional to dose. Ninety percent steady state levels are reached by day 4-5 with multiple once daily dosing.</p><p>Administration of a loading dose (on day 1) of twice the usual daily dose enables plasma levels to approximate to 90% steady-state levels by day 2.</p><p><strong><u>Distribution</u></strong></p><p>The apparent volume of distribution approximates to total body water. Plasma protein binding is low (11-12%).</p><p>Fluconazole achieves good penetration in all body fluids studied. The levels of fluconazole in saliva and sputum are similar to plasma levels. In patients with fungal meningitis, fluconazole levels in the CSF are approximately 80% the corresponding plasma levels.</p><p>High skin concentration of fluconazole, above serum concentrations, are achieved in the stratum corneum, epidermisdermis and eccrine sweat. Fluconazole accumulates in the stratum corneum. &nbsp;At a dose of 50 mg once daily, the concentration of fluconazole after 12 days was 73 &mu;g/g and 7 days after cessation of treatment the concentration was still 5.8 &mu;g/g. At the 150 mg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;once-a-week dose, the concentration of fluconazole in stratum corneum on day 7 was 23.4 &mu;g/g and 7 days after the second dose was still 7.1 &mu;g/g.</p><p>Concentration of fluconazole in nails after 4 months of 150 mg once-a-week dosing was &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.05 &mu;g/g in healthy and 1.8 &mu;g/g in diseased nails; and, fluconazole was still measurable in nail samples 6 months after the end of therapy.</p><p><strong><u>Biotransformation</u></strong></p><p>Fluconazole is metabolised only to a minor extent. Of a radioactive dose, only 11% is excreted in a changed form in the urine. Fluconazole is a moderate inhibitor of the isozymes CYP2C9 and CYP3A4 (see section 4.5). Fluconazole is also a strong inhibitor of the isozyme CYP2C19.</p><p><strong><u>Elimination</u></strong></p><p>Plasma elimination half-life for fluconazole is approximately 30 hours. The major route of excretion is renal, with approximately 80% of the administered dose appearing in the urine as unchanged medicinal product. Fluconazole clearance is proportional to creatinine clearance. There is no evidence of circulating metabolites.</p><p>The long plasma elimination half-life provides the basis for single dose therapy for vaginal candidiasis, once daily and once weekly dosing for other indications.</p><p><strong><u>Pharmacokinetics in renal impairment</u></strong></p><p>In patients with severe renal insufficiency, (GFR&lt; 20 ml/min) half life increased from 30 to 98 hours. Consequently, reduction of the dose is needed. Fluconazole is removed by haemodialysis and to a lesser extent by peritoneal dialysis. After three hours of haemodialysis session, around 50% of fluconazole is eliminated from blood.</p><p><strong><u>Pharmacokinetics during lactation</u></strong></p><p>A pharmacokinetic study in ten lactating women, who had temporarily or permanently stopped breast-feeding their infants, evaluated fluconazole concentrations in plasma and breast milk for 48 hours following a single 150 mg dose of fluconazole. Fluconazole was detected in breast milk at an average concentration of approximately 98% of those in maternal plasma. The mean peak breast milk concentration was 2.61 mg/L at 5.2 hours post-dose. The estimated daily infant dose of fluconazole from breast milk (assuming mean milk consumption of 150 ml/kg/day) based on the mean peak milk concentration is 0.39 mg/kg/day, which is approximately 40% of the recommended neonatal dose (&lt;2 weeks of age) or 13% of the recommended infant dose for mucosal candidiasis.</p><p><strong><u>Pharmacokinetics in children</u></strong></p><p>Pharmacokinetic data were assessed for 113 paediatric patients from 5 studies; 2 single-dose studies, 2 multiple-dose studies, and a study in premature neonates. Data from one study were not interpretable due to changes in formulation pathway through the study. Additional data were available from a compassionate use study.</p><p>After administration of 2-8 mg/kg fluconazole to children between the ages of 9 months to 15 years, an AUC of about 38 &mu;g&middot;h/ml was found per 1 mg/kg dose units. The average fluconazole plasma elimination half-life varied between 15 and</p><p>18 hours and the distribution volume was approximately 880 ml/kg after multiple doses. A higher fluconazole plasma elimination half-life of approximately 24 hours was found after a single dose. This is comparable with the fluconazole plasma elimination half-life after a single administration of 3 mg/kg i.v. to children of 11 days-11 months old. The distribution volume in this age group was about 950 ml/kg.</p><p>Experience with fluconazole in neonates is limited to pharmacokinetic studies in premature newborns. The mean age at first dose was 24 hours (range 9-36 hours) and mean birth weight was 0.9 kg (range 0.75-1.10 kg) for 12 pre-term neonates of average gestation around 28 weeks. Seven patients completed the protocol; a maximum of five 6 mg/kg intravenous infusions of fluconazole were administered every 72 hours. &nbsp;&nbsp;&nbsp;</p><p>The mean half-life (hours) was 74 (range 44-185) on day 1 which decreased, with time to a mean of 53 (range 30-131) on day 7 and 47 (range 27-68) on day 13. The area under the curve (microgram.h/ml) was 271 (range 173-385) on day 1 and increased with a mean of 490 (range 292-734) on day 7 and decreased with a mean of 360 (range 167-566) on day 13. The volume of distribution (ml/kg) was 1183 (range 1070-1470) on day 1 and increased, with time, to a mean of 1184 (range 510-2130) on day 7 and 1328 (range 1040-1680) on day 13.</p><p><strong><u>Pharmacokinetics in elderly</u></strong></p><p>A pharmacokinetic study was conducted in 22 subjects, 65 years of age or older receiving a single 50 mg oral dose of fluconazole. Ten of these patients were concomitantly receiving diuretics. The C<sub>max</sub> was 1.54 &mu;g/ml and occurred at 1.3 hours post-dose. The mean AUC was 76.4 &plusmn; 20.3 &mu;g&middot;h/ml, and the mean terminal half-life was 46.2 hours. These pharmacokinetic parameter values are higher than analogous values reported for normal young male volunteers.</p><p>Co-administration of diuretics did not significantly alter AUC or C<sub>max</sub>. In addition, creatinine clearance (74 ml/min), the percent of medicinal product recovered unchanged in urine (0-24 h, 22%) and the fluconazole renal clearance estimates (0.124 ml/min/kg) for the elderly were generally lower than those of younger volunteers. Thus, the alteration of fluconazole disposition in the elderly appears to be related to reduced renal function characteristics of this group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the human exposure indicating little relevance to clinical use.</p><p><strong><u>Carcinogenesis</u></strong></p><p>Fluconazole showed no evidence of carcinogenic potential in mice and rats treated orally for 24 months at doses of 2.5, 5, or 10 mg/kg/day (approximately 2-7 times the recommended human dose). Male rats treated with 5 and 10 mg/kg/day had an increased incidence of hepatocellular adenomas.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Mutagenesis </u></strong></p><p>Fluconazole, with or without metabolic activation, was negative in tests for mutagenicity in 4 strains of Salmonella typhimurium, and in the mouse lymphoma L5178Y system. Cytogenetic studies in vivo (murine bone marrow cells, following oral administration of fluconazole) and in vitro (human lymphocytes exposed to fluconazole at 1000 &mu;g/ml) showed no evidence of chromosomal mutations.</p><p><strong><u>Reproductive toxicity</u></strong></p><p>Fluconazole did not affect the fertility of male or female rats treated orally with daily doses of 5, 10, or 20 mg/kg or with parenteral doses of 5, 25, or 75 mg/kg.</p><p>There were no foetal effects at 5 or 10 mg/kg; increases in foetal anatomical variants (supernumerary ribs, renal pelvis dilation) and delays in ossification were observed at 25 and 50 mg/kg and higher doses. At doses ranging from 80 mg/kg to 320 mg/kg embryolethality in rats was increased and foetal abnormalities included wavy ribs, cleft palate, and abnormal cranio-facial ossification.</p><p>The onset of parturition was slightly delayed at 20 mg/kg orally and dystocia and prolongation of parturition were observed in a few dams at 20 mg/kg and 40 mg/kg intravenously. The disturbances in parturition were reflected by a slight increase in the number of still-born pups and decrease of neonatal survival at these dose levels. These effects on parturition are consistent with the species specific oestrogen-lowering property produced by high doses of fluconazole.</p><p>Such a hormone change has not been observed in women treated with fluconazole (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" align="left" style="width:564px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredient:</u></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Lactose monohydrate (Dense)</p></td></tr><tr><td style="vertical-align:top"><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Maize starch (Dried)</p></td></tr><tr><td style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Sodium lauryl sulphate</p></td></tr><tr><td style="vertical-align:top"><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Colloidal silicon dioxide (Aerosil 200)</p></td></tr><tr><td style="vertical-align:top"><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p></td></tr><tr><td style="vertical-align:top"><p>6.&nbsp;&nbsp;&nbsp;&nbsp; Empty hard gelatin capsule size &ldquo;1&rdquo;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; One capsule in an Alu-PVC (white) blister strip, 1 blister strip packed in a printed box along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street.
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.:   (9717) 2 461 461
Fax No.:   (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05. August. 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>